Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

Abstract

The advent of neuroimmunology has dismantled the traditional doctrine of the brain's immune privilege, uncovering a sophisticated and dynamic bidirectional regulatory interplay between the nervous and immune systems. This review synthesizes pivotal advances in neuroimmunology, integrating recent anatomical and molecular discoveries to refine the understanding of neuro-immune communication. It highlights the pathological roles of neurotransmitters, cytokines, and their signaling networks in neurodegenerative, psychiatric, and neoplastic diseases, while critically examining contested regulatory mechanisms. The review further evaluates the clinical translational potential and challenges of innovative strategies such as vagus nerve stimulation, optogenetics, multiomics sequencing, and cytokine-targeted therapies. By integrating multidisciplinary perspectives, this review consolidates a theoretical framework for neuro-immune research and provides insights into precision medicine for related diseases. On the basis of synthesizing existing knowledge, it proposes promising research directions, identifies priorities and potential challenges for future investigations, and emphasizes the value of neuro-immune mechanisms in guiding therapeutic development—including target identification, design of individualized treatment strategies, and cross-disciplinary collaborative innovation to advance clinical interventions for neuro-immune diseases. Finally, the review delves into the recent advances and challenges in combined neuromodulation-immunotherapy strategies.

Keywords

neuroimmunology / neuromodulation / neuro-immune crosstalk / immunomodulation

References

[1] R. Virchow, Gesammelte Abhandlungen zur Wissenschaftlichen Medicin (Frankfurt a.M.: Verlag von Meidinger Sohn, 1856): 1024.

[2] A. Sierra, F. de Castro, J. Del Rio-Hortega, et al., “The ”Big-Bang“ for Modern Glial Biology: Translation and Comments on Pio del Rio-Hortega 1919 Series of Papers on Microglia,” Glia 64, no. 11 (2016): 1801–1840.

[3] P. Ehrlich, Das Sauerstoff-Bedürfniss Des Organismus: Eine Farbenanalytische Studie (Berlin: August Hirschwald, 1885): 1–167.

[4] E. E. Goldmann, Vitalfärbung am Zentralnervensystem: Beitrag Zur Physio‑Pathologie des Plexus Chorioideus und der Hirnhäute (Berlin: Königliche Akademie der Wissenschaften, 1913): 1–60.

[5] Y. Shirai, “On the Transplantation of the Rat Sarcoma in Adult Heterogenous Animals,” Japanese Medical World 1 (1921): 14–15.

[6] P. B. Medawar, “Immunity to Homologous Grafted Skin; the Fate of Skin Homografts Transplanted to the Brain, to Subcutaneous Tissue, and to the Anterior Chamber of the Eye,” British Journal of Experimental Pathology 29, no. 1 (1948): 58–69.

[7] G. W. Harris, “Neural Control of the Pituitary Gland,” Physiological Reviews 28, no. 2 (1948): 139–179.

[8] G. W. Harris, “Neural Control of the Pituitary Gland. II. The Adenohypophysis, With Special Reference to the Secretion of A.C.T.H,” British Medical Journal 2, no. 4732 (1951): 627–634.

[9] R. Ader and N. Cohen, “Behaviorally Conditioned Immunosuppression,” Psychosomatic Medicine 37, no. 4 (1975): 333–340.

[10] R. Ader and N. Cohen, “Behaviorally Conditioned Immunosuppression and Murine Systemic Lupus Erythematosus,” Science 215, no. 4539 (1982): 1534–1536.

[11] H. Besedovsky and E. Sorkin, “Network of Immune-neuroendocrine Interactions,” Clinical and Experimental Immunology 27, no. 1 (1977): 1–12.

[12] U. Traugott, E. L. Reinherz, and C. S. Raine, “Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions,” Science 219, no. 4582 (1983): 308–310.

[13] W. F. Hickey, B. L. Hsu, and H. Kimura, “T-lymphocyte Entry Into the central Nervous System,” Journal of Neuroscience Research 28, no. 2 (1991):254–260.

[14] O. Rapalino, O. Lazarov-Spiegler, E. Agranov, et al., “Implantation of Stimulated Homologous Macrophages Results in Partial Recovery of Paraplegic Rats,” Nature Medicine 4, no. 7 (1998): 814–821.

[15] G. Moalem, R. Leibowitz-Amit, E. Yoles, et al., “Autoimmune T Cells Protect Neurons From Secondary Degeneration After central Nervous System Axotomy,” Nature Medicine 5, no. 1 (1999): 49–55.

[16] K. J. Tracey, “The Inflammatory Reflex,” Nature 420, no. 6917 (2002):853–859.

[17] S. A. Wolf, B. Steiner, A. Akpinarli, et al., “CD4-positive T Lymphocytes Provide a Neuroimmunological Link in the Control of Adult Hippocampal Neurogenesis,” Journal of Immunology 182, no. 7 (2009):3979–3984.

[18] C. T. Ekdahl, J. H. Claasen, S. Bonde, Z. Kokaia, and O. Lindvall, “Inflammation Is Detrimental for Neurogenesis in Adult Brain,” Proceedings of the National Academy of Sciences of of the United States of America 100, no. 23 (2003): 13632–13637.

[19] J. P. Konsman, P. Parnet, and R. Dantzer, “Cytokine-induced Sickness Behaviour: Mechanisms and Implications,” Trends in Neuroscience (Tins) 25, no. 3 (2002): 154–159.

[20] K. W. Kelley, R. M. Bluthe, R. Dantzer, et al., “Cytokine-induced Sickness Behavior,” Brain, Behavior, and Immunity 17, no. Suppl 1 (2003): S112–S118.

[21] W. C. Poller, J. Downey, A. A. Mooslechner, et al., “Brain Motor and Fear Circuits Regulate Leukocytes During Acute Stress,” Nature 607, no. 7919 (2022): 578–584.

[22] G. Castellani, T. Croese, J. M. Peralta Ramos, and M. Schwartz, “Transforming the Understanding of Brain Immunity,” Science 380, no. 6640 (2023): eabo7649.

[23] A. Saunders, K. W. Huang, C. Vondrak, et al., “Ascertaining Cells' synaptic Connections and RNA Expression Simultaneously With Barcoded rabies Virus Libraries,” Nature Communications 13, no. 1 (2022): 6993.

[24] M. A. Wheeler, “Interactions Between Immune Cells Recorded,” Nature 627, no. 8003 (2024): 277–279.

[25] D. Kirschenbaum, K. Xie, F. Ingelfinger, et al., “Time-resolved Single-cell Transcriptomics Defines Immune Trajectories in Glioblastoma,” Cell 187, no. 1 (2024): 149–165. e23.

[26] J. H. Marshel, Y. S. Kim, T. A. Machado, et al., “Cortical Layer-specific Critical Dynamics Triggering Perception,” Science 365, no. 6453 (2019): eaaw5202.

[27] J. Park, J. Wang, W. Guan, et al., “Integrated Platform for Multiscale Molecular Imaging and Phenotyping of the human Brain,” Science 384, no. 6701 (2024): eadh9979.

[28] A. Louveau, I. Smirnov, T. J. Keyes, et al., “Structural and Functional Features of central Nervous System Lymphatic Vessels,” Nature 523, no. 7560 (2015): 337–341.

[29] D. Gosselin, D. Skola, N. G. Coufal, et al., “An Environment-dependent Transcriptional Network Specifies human Microglia Identity,” Science 356, no. 6344 (2017).

[30] P. J. Goadsby, U. Reuter, Y. Hallstrom, et al., “A Controlled Trial of Erenumab for Episodic Migraine,” New England Journal of Medicine 377, no. 22 (2017): 2123–2132.

[31] G. M. Haig, E. E. Bain, W. Z. Robieson, J. D. Baker, and A. A. Othman, “A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective alpha7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia,” American Journal of Psychiatry 173, no. 8 (2016): 827–835.

[32] D. Volc, W. Poewe, A. Kutzelnigg, et al., “Safety and Immunogenicity of the Alpha-synuclein Active Immunotherapeutic PD01A in Patients With Parkinson's Disease: A Randomised, Single-blinded, Phase 1 Trial,” Lancet Neurology 19, no. 7 (2020): 591–600.

[33] Y. D. Mai, Q. Zhang, C. L. Fung, S. O. Leung, and C. H. Chong, “CD22 modulation Alleviates Amyloid Beta-induced Neuroinflammation,” Journal of Neuroinflammation 22, no. 1 (2025): 32.

[34] J. R. Klein, “Dynamic Interactions between the Immune System and the Neuroendocrine System in Health and Disease,” Frontiers in Endocrinology (Lausanne) 12 (2021): 655982.

[35] L. Ulloa, S. Quiroz-Gonzalez, and R. Torres-Rosas, “Nerve Stimulation: Immunomodulation and Control of Inflammation,” Trends in Molecular Medicine 23, no. 12 (2017): 1103–1120.

[36] Y. Li, M. Yang, F. Wu, et al., “Mechanism of Electroacupuncture on Inflammatory Pain: Neural-immune-endocrine Interactions,” Journal of Traditional Chinese Medicine 39, no. 5 (2019): 740–749.

[37] H. Lehtonen, H. Jokela, J. Hofmann, et al., “Early Precursor-derived Pituitary Gland Tissue-resident Macrophages Play a Pivotal Role in Modulating Hormonal Balance,” Cell Reports 44, no. 2 (2025): 115227.

[38] T. Yan, R. Wang, J. Yao, and M. Luo, “Single-cell Transcriptomic Analysis Reveals Rich Pituitary-Immune Interactions Under Systemic Inflammation,” PLoS Biology 21, no. 12 (2023): e3002403.

[39] Y. Xu, J. Yan, Y. Tao, et al., “Pituitary Hormone Alpha-MSH Promotes Tumor-induced Myelopoiesis and Immunosuppression,” Science 377, no. 6610 (2022): 1085–1091.

[40] N. P. Jaschke, D. Breining, M. Hofmann, et al., “Small-molecule CBP/p300 Histone Acetyltransferase Inhibition Mobilizes Leukocytes From the Bone Marrow via the Endocrine Stress Response,” Immunity 57, no. 2 (2024): 364–378. e9.

[41] L. P. Wachsmuth, E. S. Srinivasan, B. J. Puviindran, et al., “Autonomic Modulation of the Immune Response and Implications for CNS Malignancies,” NPJ Precision Oncology 9, no. 1 (2025): 168.

[42] S. Udit, K. Blake, and I. M. Chiu, “Somatosensory and Autonomic Neuronal Regulation of the Immune Response,” Nature Reviews Neuroscience 23, no. 3 (2022): 157–171.

[43] F. Marino and M. Cosentino, “Adrenergic Modulation of Immune Cells: An Update,” Amino Acids 45, no. 1 (2013): 55–71.

[44] A. W. Tank and D. L. Wong, “Peripheral and central Effects of Circulating Catecholamines,” Comprehensive Physiology 5, no. 1 (2015): 1–15.

[45] M. Schiller, T. L. Ben-Shaanan, and A. Rolls, “Neuronal Regulation of Immunity: Why, How and Where?,” Nature Reviews Immunology 21, no. 1 (2021): 20–36.

[46] M. J. Loza, S. P. Peters, S. Foster, I. U. Khan, and R. B. Penn, “beta-Agonist Enhances Type 2 T-cell Survival and Accumulation,” Journal of Allergy and Clinical Immunology 119, no. 1 (2007): 235–244.

[47] E. Chelmicka-Schorr, M. N. Kwasniewski, and A. Czlonkowska, “Sympathetic Nervous System Modulates Macrophage Function,” International Journal of Immunopharmacology 14, no. 5 (1992): 841–846.

[48] H. G. Schaible and R. H. Straub, “Function of the Sympathetic Supply in Acute and Chronic Experimental Joint Inflammation,” Autonomic Neuroscience 182 (2014): 55–64.

[49] L. D. Estrada, D. Agac, and J. D. Farrar, “Sympathetic Neural Signaling via the beta2-adrenergic Receptor Suppresses T-cell Receptor-mediated human and Mouse CD8(+) T-cell Effector Function,” European Journal of Immunology 46, no. 8 (2016): 1948–1958.

[50] A. Rolls, W. W. Pang, I. Ibarra, et al., “Sleep Disruption Impairs Haematopoietic Stem Cell Transplantation in Mice,” Nature Communications 6 (2015): 8516.

[51] Z. You, B. Liu, and H. Qi, “Neuronal Regulation of B-cell Immunity: Anticipatory Immune Posturing?,” Neuron 110, no. 21 (2022): 3582–3596.

[52] M. Maes, A. Lin, G. Kenis, B. Egyed, and E. Bosmans, “The Effects of Noradrenaline and Alpha-2 Adrenoceptor Agents on the Production of Monocytic Products,” Psychiatry Research 96, no. 3 (2000): 245–253.

[53] E. Goyarts, M. Matsui, T. Mammone, et al., “Norepinephrine Modulates human Dendritic Cell Activation by Altering Cytokine Release,” Experimental Dermatology 17, no. 3 (2008): 188–196.

[54] P. Panina-Bordignon, D. Mazzeo, P. D. Lucia, et al., “Beta2-agonists Prevent Th1 Development by Selective Inhibition of Interleukin 12,” Journal of Clinical Investigation 100, no. 6 (1997): 1513–1519.

[55] M. G. Guereschi, L. P. Araujo, J. T. Maricato, et al., “Beta2-adrenergic Receptor Signaling in CD4+ Foxp3+ Regulatory T Cells Enhances Their Suppressive Function in a PKA-dependent Manner,” European Journal of Immunology 43, no. 4 (2013): 1001–1012.

[56] H. C. Xu, B. Wu, Y. M. Ma, et al., “Hederacoside-C Protects Against AGEs-induced ECM Degradation in Mice Chondrocytes,” International Immunopharmacology 84 (2020): 106579.

[57] C. S. Chen, J. Weber, S. J. Holtkamp, et al., “Loss of Direct Adrenergic Innervation After Peripheral Nerve Injury Causes Lymph Node Expansion Through IFN-gamma,” Journal of Experimental Medicine 218, no. 8 (2021): e20202377.

[58] M. Maryanovich, A. H. Zahalka, H. Pierce, et al., “Adrenergic Nerve Degeneration in Bone Marrow Drives Aging of the Hematopoietic Stem Cell Niche,” Nature Medicine 24, no. 6 (2018): 782–791.

[59] T. Heidt, H. B. Sager, G. Courties, et al., “Chronic Variable Stress Activates Hematopoietic Stem Cells,” Nature Medicine 20, no. 7 (2014): 754–758.

[60] D. L. Bellinger and D. Lorton, “Autonomic Regulation of Cellular Immune Function,” Autonomic Neuroscience 182 (2014): 15–41.

[61] F. A. Koopman, S. S. Chavan, S. Miljko, et al., “Vagus Nerve Stimulation Inhibits Cytokine Production and Attenuates Disease Severity in Rheumatoid Arthritis,” Proceedings of the National Academy of Sciences of of the United States of America 113, no. 29 (2016): 8284–8289.

[62] V. Sinniger, S. Pellissier, F. Fauvelle, et al., “A 12-month Pilot Study Outcomes of Vagus Nerve Stimulation in Crohn's disease,” Neurogastroenterology and Motility 32, no. 10 (2020): e13911.

[63] L. Ma, H. B. Wang, and K. Hashimoto, “The Vagus Nerve: An Old but New Player in Brain-body Communication,” Brain, Behavior, and Immunity 124 (2025): 28–39.

[64] J. Shanks, M. Pachen, J. W. Chang, B. George, and R. Ramchandra, “Cardiac Vagal Nerve Activity Increases during Exercise to Enhance Coronary Blood Flow,” Circulation Research 133, no. 7 (2023): 559–571.

[65] N. F. Modares, L. D. Hendrikse, L. K. Smith, et al., “B Cell-derived Acetylcholine Promotes Liver Regeneration by Regulating Kupffer Cell and Hepatic CD8(+) T Cell Function,” Immunity 58, no. 5 (2025): 1201–1216. e7.

[66] M. Skok, R. Grailhe, F. Agenes, and J. P. Changeux, “The Role of Nicotinic Acetylcholine Receptors in Lymphocyte Development,” Journal of Neuroimmunology 171, no. 1–2 (2006): 86–98.

[67] A. E. Siniavin, M. A. Streltsova, D. S. Kudryavtsev, et al., “Activation of alpha7 Nicotinic Acetylcholine Receptor Upregulates HLA-DR and Macrophage Receptors: Potential Role in Adaptive Immunity and in Preventing Immunosuppression,” Biomolecules 10, no. 4 (2020): 507.

[68] J. Wang, R. Li, Z. Peng, et al., “GTS-21 Reduces Inflammation in Acute Lung Injury by Regulating M1 Polarization and Function of Alveolar Macrophages,” Shock (Augusta, Ga) 51, no. 3 (2019): 389–400.

[69] S. R. Zanetti, A. Ziblat, N. I. Torres, N. W. Zwirner, and C. Bouzat, “Expression and Functional Role of alpha7 Nicotinic Receptor in Human Cytokine-stimulated Natural Killer (NK) Cells,” Journal of Biological Chemistry 291, no. 32 (2016): 16541–16552.

[70] A. Yang, C. H. Wu, S. Matsuo, et al., “Activation of the alpha7nAChR by GTS-21 Mitigates Septic Tubular Cell Injury and Modulates Macrophage Infiltration,” International Immunopharmacology 138 (2024): 112555.

[71] L. Deng, J. E. Gillis, I. M. Chiu, and D. H. Kaplan, “Sensory Neurons: An Integrated Component of Innate Immunity,” Immunity 57, no. 4 (2024): 815–831.

[72] A. Sepahi, A. Kraus, E. Casadei, et al., “Olfactory Sensory Neurons Mediate Ultrarapid Antiviral Immune Responses in a TrkA-dependent Manner,” Proceedings of the National Academy of Sciences of of the United States of America 116, no. 25 (2019): 12428–12436.

[73] O. Erdogan, X. Q. Hu, and I. M. Chiu, “Sensory Neurons on Guard: Roles in Pathogen Defense and Host Immunity,” Current Opinion in Immunology 93 (2025): 102541.

[74] I. Isorna, M. A. Gonzalez-Moles, M. Munoz, and F. Esteban, “Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies,” Journal of Clinical Medicine 12, no. 19 (2023): 6409.

[75] V. Padmanaban, I. Keller, E. S. Seltzer, et al., “Neuronal Substance P Drives Metastasis Through an Extracellular RNA-TLR7 Axis,” Nature 633, no. 8028 (2024): 207–215.

[76] M. Tamari, K. L. Del Bel, A. M. Ver Heul, et al., “Sensory Neurons Promote Immune Homeostasis in the Lung,” Cell 187, no. 1 (2024): 44–61. e17.

[77] From the American Association of Neurological Surgeons, A.S.o.N.C., C.I.R.A.C.o.N.S.E.S.o.M.I.N.T.E.S.o.N.E.S.O.S.f.C.A. Interventional Radiology Society of Europe, S.o.I.R.S.o.N.S. Interventions, et al., “Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke,” International Journal of Stroke 13, 6 (2018): 612–632.

[78] T. Saraiva-Santos, T. H. Zaninelli, and F. A. Pinho-Ribeiro, “Modulation of Host Immunity by Sensory Neurons,” Trends in Immunology 45, no. 5 (2024): 381–396.

[79] Y. Lu, Y. Huang, J. Li, et al., “Eosinophil Extracellular Traps Drive Asthma Progression Through Neuro-immune Signals,” Nature Cell Biology 23, no. 10 (2021): 1060–1072.

[80] J. X. Duan, Y. Zhou, A. Y. Zhou, et al., “Calcitonin Gene-related Peptide Exerts Anti-inflammatory Property Through Regulating Murine Macrophages Polarization in Vitro,” Molecular Immunology 91 (2017): 105–113.

[81] Y. Wan, C. Cao, and W. Zeng, “The Sympathetic Neurons in the Gut: Perspectives on Metabolic and Immune Health and Diseases,” Current Opinion in Neurobiology 93 (2025): 103051.

[82] D. Ramanan, A. Pratama, Y. Zhu, et al., “Regulatory T Cells in the Face of the Intestinal Microbiota,” Nature Reviews Immunology 23, no. 11 (2023): 749–762.

[83] J. W. Bostick and L. Zhou, “Neuro-immune Crosstalk: Focus on Innate Lymphoid Cells,” Trends in Immunology 46, no. 8 (2025): 559–561.

[84] A. Mashaghi, A. Marmalidou, M. Tehrani, et al., “Neuropeptide Substance P and the Immune Response,” Cellular and Molecular Life Sciences 73, no. 22 (2016): 4249–4264.

[85] I. Chernova, J. P. Lai, H. Li, et al., “Substance P (SP) Enhances CCL5-induced Chemotaxis and Intracellular Signaling in human Monocytes, Which Express the Truncated Neurokinin-1 Receptor (NK1R),” Journal of Leukocyte Biology 85, no. 1 (2009): 154–164.

[86] W. Zhang, M. Lyu, N. J. Bessman, et al., “Gut-innervating Nociceptors Regulate the Intestinal Microbiota to Promote Tissue Protection,” Cell 185, no. 22 (2022): 4170–4189. e20.

[87] F. A. Pinho-Ribeiro, B. Baddal, R. Haarsma, et al., “Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection,” Cell 173, no. 5 (2018): 1083–1097. e22.

[88] S. W. Kashem, M. S. Riedl, C. Yao, et al., “Nociceptive Sensory Fibers Drive Interleukin-23 Production From CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity,” Immunity 43, no. 3 (2015): 515–526.

[89] M. Wu, G. Song, J. Li, et al., “Innervation of Nociceptor Neurons in the Spleen Promotes Germinal Center Responses and Humoral Immunity,” Cell 187, no. 12 (2024): 2935–2951. e19.

[90] Y. Hou, L. Sun, M. W. LaFleur, et al., “Neuropeptide Signalling Orchestrates T Cell Differentiation,” Nature 635, no. 8038 (2024): 444–452.

[91] D. Riga, K. L. Kooij, K. Rademakers, et al., “Neuropeptide Y Neurons Surrounding the Locus Coeruleus Inhibit Noradrenergic System Activity to Reduce Anxiety,” Science Advances 11, no. 30 (2025): eadq0011.

[92] W. Wang, H. Yang, T. Passang, et al., “Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis,” Cancer Letters 628 (2025): 217855.

[93] X. Zhang, B. Lei, Y. Yuan, et al., “Brain Control of Humoral Immune Responses Amenable to Behavioural Modulation,” Nature 581, no. 7807 (2020): 204–208.

[94] B. O. Bratton, D. Martelli, M. J. McKinley, et al., “Neural Regulation of Inflammation: No Neural Connection From the Vagus to Splenic Sympathetic Neurons,” Experimental Physiology 97, no. 11 (2012): 1180–1185.

[95] C. L. Kaestner, E. H. Smith, S. G. Peirce, and D. B. Hoover, “Immunohistochemical Analysis of the Mouse Celiac Ganglion: An Integrative Relay Station of the Peripheral Nervous System,” Journal of Comparative Neurology 527, no. 16 (2019): 2742–2760.

[96] S. Devi, Y. O. Alexandre, J. K. Loi, et al., “Adrenergic Regulation of the Vasculature Impairs Leukocyte Interstitial Migration and Suppresses Immune Responses,” Immunity 54, no. 6 (2021): 1219–1230. e7.

[97] J. Yu, K. Xiao, X. Chen, et al., “Neuron-derived Neuropeptide Y Fine-tunes the Splenic Immune Responses,” Neuron 110, no. 8 (2022): 1327–1339. e6.

[98] N. Khan, S. Kaur, C. M. Knuth, and M. G. Jeschke, “CNS-Spleen Axis—a Close Interplay in Mediating Inflammatory Responses in Burn Patients and a Key to Novel Burn Therapeutics,” Frontiers in Immunology 12 (2021): 720221.

[99] M. Rosas-Ballina and K. J. Tracey, “Cholinergic Control of Inflammation,” Journal of Internal Medicine 265, no. 6 (2009): 663–679.

[100] V. A. Pavlov, H. Wang, C. J. Czura, S. G. Friedman, and K. J. Tracey, “The Cholinergic Anti-inflammatory Pathway: A Missing Link in Neuroimmunomodulation,” Molecular Medicine 9, no. 5–8 (2003): 125–134.

[101] X. Zhu, J. Y. Huang, W. Y. Dong, et al., “Somatosensory Cortex and central Amygdala Regulate Neuropathic Pain-mediated Peripheral Immune Response via Vagal Projections to the Spleen,” Nature Neuroscience 27, no. 3 (2024): 471–483.

[102] Y. Bai, H. Ren, S. Leng, et al., “CD8(+)GZMK(+)CD27(+)CCR7(+) T Cells Mobilized by Splenic Sympathetic Nerves Aggravate Brain Ischemia‒Reperfusion Injury via CCL19-positive Endothelial Cells,” Cellular & Molecular Immunology (2025).

[103] L. A. Grisanti, A. P. Woster, J. Dahlman, et al., “alpha1-adrenergic Receptors Positively Regulate Toll-Like Receptor Cytokine Production From human Monocytes and Macrophages,” Journal of Pharmacology and Experimental Therapeutics 338, no. 2 (2011): 648–657.

[104] D. M. Nance and V. M. Sanders, “Autonomic Innervation and Regulation of the Immune System (1987-2007),” Brain, Behavior, and Immunity 21, no. 6 (2007): 736–745.

[105] J. Yu, K. Xiao, X. Chen, et al., “Neuron-derived Neuropeptide Y Fine-tunes the Splenic Immune Responses,” Neuron 111, no. 8 (2023): 1346–1347.

[106] F. K. Swirski, M. Nahrendorf, M. Etzrodt, et al., “Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites,” Science 325, no. 5940 (2009): 612–616.

[107] J. M. Huston, M. Ochani, M. Rosas-Ballina, et al., “Splenectomy Inactivates the Cholinergic Antiinflammatory Pathway During Lethal Endotoxemia and Polymicrobial Sepsis,” Journal of Experimental Medicine 203, no. 7 (2006): 1623–1628.

[108] E. Semaeva, O. Tenstad, J. Skavland, et al., “Access to the Spleen Microenvironment Through Lymph Shows Local Cytokine Production, Increased Cell Flux, and Altered Signaling of Immune Cells During Lipopolysaccharide-induced Acute Inflammation,” Journal of Immunology 184, no. 8 (2010): 4547–4556.

[109] D. E. Akinyemi, R. Chevre, and O. Soehnlein, “Neuro-immune Crosstalk in Hematopoiesis, Inflammation, and Repair,” Trends in Immunology 45, no. 8 (2024): 597–608.

[110] S. Fujita, T. Morikawa, S. Tamaki, et al., “Quantitative Analysis of Sympathetic and Nociceptive Innervation across Bone Marrow Regions in Mice,” Experimental Hematology 112–113 (2022): 44–59. e6.

[111] S. Chhatar and G. Lal, “Role of Adrenergic Receptor Signalling in Neuro-immune Communication,” Current Research in Immunology 2 (2021): 202–217.

[112] S. Pinho and P. S. Frenette, “Haematopoietic Stem Cell Activity and Interactions With the Niche,” Nature Reviews Molecular Cell Biology 20, no. 5 (2019): 303–320.

[113] S. Mendez-Ferrer, D. Lucas, M. Battista, and P. S. Frenette, “Haematopoietic Stem Cell Release Is Regulated by Circadian Oscillations,” Nature 452, no. 7186 (2008): 442–447.

[114] S. Mendez-Ferrer, T. V. Michurina, F. Ferraro, et al., “Mesenchymal and Haematopoietic Stem Cells Form a Unique Bone Marrow Niche,” Nature 466, no. 7308 (2010): 829–834.

[115] M. H. Park, H. K. Jin, W. K. Min, et al., “Neuropeptide Y Regulates the Hematopoietic Stem Cell Microenvironment and Prevents Nerve Injury in the Bone Marrow,” Embo Journal 34, no. 12 (2015): 1648–1660.

[116] H. Pierce, D. Zhang, C. Magnon, et al., “Cholinergic Signals From the CNS Regulate G-CSF-Mediated HSC Mobilization From Bone Marrow via a Glucocorticoid Signaling Relay,” Cell Stem Cell 20, no. 5 (2017): 648–658. e4.

[117] M. Yang, Y. Li, K. Shi, et al., “Single-Cell Transcriptomes of Immune Cells From Multiple Compartments Redefine the Ontology of Myeloid Subtypes Post-Stroke,” Advanced Science (Weinheim, Germany) 12, no. 13 (2025): e2408722.

[118] X. Gao, D. Zhang, C. Xu, et al., “Nociceptive Nerves Regulate Haematopoietic Stem Cell Mobilization,” Nature 589, no. 7843 (2021): 591–596.

[119] W. Liu, W. Chen, M. Xie, et al., “Traumatic Brain Injury Stimulates Sympathetic Tone-mediated Bone Marrow Myelopoiesis to Favor Fracture Healing,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 260.

[120] C. Fielding, A. Garcia-Garcia, C. Korn, et al., “Cholinergic Signals Preserve Haematopoietic Stem Cell Quiescence During Regenerative Haematopoiesis,” Nature Communications 13, no. 1 (2022): 543.

[121] P. Y. Sun, J. Liu, J. N. Hu, et al., “Rejuvenation of Peripheral Immune Cells Attenuates Alzheimer's Disease-Like Pathologies and Behavioral Deficits in a Mouse Model,” Science Advances 10, no. 22 (2024): eadl1123.

[122] X. A. Zhu, S. Starosta, M. Ferrer, et al., “A Neuro-immune Circuit Mediates Cancer Cachexia-associated Apathy,” Science 388, no. 6743 (2025): eadm8857.

[123] B. Becher, T. Derfuss, and R. Liblau, “Targeting Cytokine Networks in Neuroinflammatory Diseases,” Nature Reviews Drug Discovery 23, no. 11 (2024): 862–879.

[124] B. Becher, S. Spath, and J. Goverman, “Cytokine Networks in Neuroinflammation,” Nature Reviews Immunology 17, no. 1 (2017): 49–59.

[125] D. Mrdjen, A. Pavlovic, F. J. Hartmann, et al., “High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease,” Immunity 48, no. 2 (2018): 380–395. e6.

[126] L. Yang, K. Mao, H. Yu, and J. Chen, “Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets,” Journal of Neuroimmune Pharmacology 15, no. 4 (2020): 830–837.

[127] H. Vida, M. Sahar, A. Nikdouz, and H. Arezoo, “Chemokines in Neurodegenerative Diseases,” Immunology and Cell Biology 103, no. 3 (2025): 275–292.

[128] L. Ye, Y. Huang, L. Zhao, et al., “IL-1beta and TNF-alpha Induce Neurotoxicity Through Glutamate Production: A Potential Role for Neuronal Glutaminase,” Journal of Neurochemistry 125, no. 6 (2013): 897–908.

[129] C. Dong, “Cytokine Regulation and Function in T Cells,” Annual Review of Immunology 39 (2021): 51–76.

[130] J. G. Jones, “Hepatic Glucose and Lipid Metabolism,” Diabetologia 59, no. 6 (2016): 1098–1103.

[131] B. Lee, J. T. Kwon, Y. Jeong, et al., “Inflammatory and Anti-inflammatory Cytokines Bidirectionally Modulate Amygdala Circuits Regulating Anxiety,” Cell 188, no. 8 (2025): 2190–2202. e15.

[132] K. Alves de Lima, J. Rustenhoven, S. Da Mesquita, et al., “Meningeal Gammadelta T Cells Regulate Anxiety-Like Behavior via IL-17a Signaling in Neurons,” Nature Immunology 21, no. 11 (2020): 1421–1429.

[133] M. D. Reed, Y. S. Yim, R. D. Wimmer, et al., “IL-17a Promotes Sociability in Mouse Models of Neurodevelopmental Disorders,” Nature 577, no. 7789 (2020): 249–253.

[134] Y. Lee, T. Ishikawa, H. Lee, et al., “Brain-wide Mapping of Immune Receptors Uncovers a Neuromodulatory Role of IL-17E and the Receptor IL-17RB,” Cell 188, no. 8 (2025): 2203–2217.

[135] T. Liu, H. Wu, and J. Wei, “Bridging the Gap: The Neuro-immune Axis as a Key Player in Neurodegenerative Disorders,” Neuroscience Bulletin (2025).

[136] M. Xia, J. Lu, J. Lan, et al., “Elevated IL-22 as a Result of Stress-induced Gut Leakage Suppresses Septal Neuron Activation to Ameliorate Anxiety-Like Behavior,” Immunity 58, no. 1 (2025): 218–231. e12.

[137] D. He, H. Xu, H. Zhang, et al., “Disruption of the IL-33-ST2-AKT Signaling Axis Impairs Neurodevelopment by Inhibiting Microglial Metabolic Adaptation and Phagocytic Function,” Immunity 55, no. 1 (2022): 159–173. e9.

[138] F. Zipp, S. Bittner, and D. P. Schafer, “Cytokines as Emerging Regulators of central Nervous System Synapses,” Immunity 56, no. 5 (2023): 914–925.

[139] Q. Bi, C. Wang, G. Cheng, et al., “Microglia-derived PDGFB Promotes Neuronal Potassium Currents to Suppress Basal Sympathetic Tonicity and Limit Hypertension,” Immunity 55, no. 8 (2022): 1466–1482.

[140] M. Colonna and O. Butovsky, “Microglia Function in the Central Nervous System during Health and Neurodegeneration,” Annual Review of Immunology 35 (2017): 441–468.

[141] H. Liu, R. K. Leak, and X. Hu, “Neurotransmitter Receptors on Microglia,” Stroke: Vascular and Interventional Neurology 1, no. 2 (2016): 52–58.

[142] K. Kim, D. Abramishvili, S. Du, et al., “Meningeal Lymphatics-microglia Axis Regulates Synaptic Physiology,” Cell 188, no. 10 (2025): 2705–2719. e23.

[143] M. Sil, N. Mukherjee, I. Chatterjee, A. Ghosh, and A. Goswami, “Glial Cells in Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Frontiers,” Journal of Molecular Neuroscience 75, no. 3 (2025): 87.

[144] J. Wu, Y. Wang, X. Li, et al., “Microglia Replacement Halts the Progression of Microgliopathy in Mice and Humans,” Science 389, no. 6756 (2025): eadr1015.

[145] K. Borst, A. A. Dumas, and M. Prinz, “Microglia: Immune and Non-immune Functions,” Immunity 54, no. 10 (2021): 2194–2208.

[146] Y. Li, H. Zhou, X. He, et al., “Impaired Microglial Glycolysis Promotes Inflammatory Responses After Intracerebral Haemorrhage via HK2-dependent Mitochondrial Dysfunction,” Journal of Advanced Research 73 (2025): 575–591.

[147] B. Han, W. Jiang, P. Cui, et al., “Microglial PGC-1alpha Protects Against Ischemic Brain Injury by Suppressing Neuroinflammation,” Genomic Medicine 13, no. 1 (2021): 47.

[148] S. S. Chavan, V. A. Pavlov, and K. J. Tracey, “Mechanisms and Therapeutic Relevance of Neuro-immune Communication,” Immunity 46, no. 6 (2017): 927–942.

[149] T. Pu, J. Sun, G. Ren, and H. Li, “Neuro-immune Crosstalk in Cancer: Mechanisms and Therapeutic Implications,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 176.

[150] B. S. Kim and D. Artis, “The Sensory Neuro-immune Frontier,” Immunity 58, no. 5 (2025): 1033–1039.

[151] L. C. D. Smyth and J. Kipnis, “Redefining CNS Immune Privilege,” Nature Reviews Immunology 25, no. 10 (2025): 766–775.

[152] C. Hours, P. Vayssiere, P. Gressens, and M. Laforge, “Immunity in Neuromodulation: Probing Neural and Immune Pathways in Brain Disorders,” Journal of Neuroinflammation 22, no. 1 (2025): 122.

[153] L. A. Hohsfield, S. J. Kim, R. A. Barahona, et al., “Identification of the Velum Interpositum as a Meningeal-CNS Route for Myeloid Cell Trafficking Into the Brain,” Neuron 113, no. 15 (2025): 2455–2473. e6.

[154] S. Zhang, Y. Gao, Y. Zhao, et al., “Peripheral and central Neuro-immune Mechanisms in Alzheimer's Disease Pathogenesis,” Molecular Neurodegeneration 20, no. 1 (2025): 22.

[155] W. Xu, X. Yang, H. Zheng, C. Chen, and J. Yuan, “Role of Tunneling Nanotubes in Neuroglia,” Neural Regeneration Research 21, no. 3 (2026): 1023–1036.

[156] T. Feng, Q. Xu, S. Wang, D. Hou, and X. Wu, “Interplay Between Tunneling Nanotubes and Wnt Signaling: Insights Into Cytoskeletal Regulation and Therapeutic Potential,” Biochemistry and Biophysics Reports 43 (2025): 102065.

[157] H. Scheiblich, F. Eikens, L. Wischhof, et al., “Microglia Rescue Neurons From Aggregate-induced Neuronal Dysfunction and Death Through Tunneling Nanotubes,” Neuron 112, no. 18 (2024): 3106–3125.

[158] H. L. Mathews and L. W. Janusek, “Epigenetics and Psychoneuroimmunology: Mechanisms and Models,” Brain, Behavior, and Immunity 25, no. 1 (2011): 25–39.

[159] A. C. Liberman, E. Trias, L. da Silva Chagas, et al., “Neuro-immune and Inflammatory Signals in Complex Disorders of the Central Nervous System,” Neuroimmunomodulation 25, no. 5–6 (2018): 246–270.

[160] M. Linnerbauer, M. A. Wheeler, and F. J. Quintana, “Astrocyte Crosstalk in CNS Inflammation,” Neuron 108, no. 4 (2020): 608–622.

[161] J. Liang, F. Yang, Z. Li, and Q. Li, “Epigenetic Regulation of the Inflammatory Response in Stroke,” Neural Regeneration Research 20, no. 11 (2025): 3045–3062.

[162] J. R. Occean, N. Yang, Y. Sun, et al., “Gene Body DNA Hydroxymethylation Restricts the Magnitude of Transcriptional Changes During Aging,” Nature Communications 15, no. 1 (2024): 6357.

[163] Q. Zhang, K. Zhao, Q. Shen, et al., “Tet2 is Required to Resolve Inflammation by Recruiting Hdac2 to Specifically Repress IL-6,” Nature 525, no. 7569 (2015): 389–393.

[164] L. Zhao, C. L. Schepp, M. Iskandar, Y. Tao, and M. Dey, “Epigenetic Regulation of Immune Cells in central Nervous System: From Steady state to Pathology,” Neurochemistry International 188 (2025): 106005.

[165] Y. Wang, D. Xu, S. Liu, et al., “Cognate Interaction-dependent Pathogenicity of Meningeal B Cells Drives Neuroinflammation Relapse,” Immunity 58, no. 9 (2025): 2256–2270.

[166] K. Hashimoto, “Emerging Role of the Host Microbiome in Neuropsychiatric Disorders: Overview and Future Directions,” Molecular Psychiatry 28, no. 9 (2023): 3625–3637.

[167] S. L. Prescott and S. D. Liberles, “Internal Senses of the Vagus Nerve,” Neuron 110, no. 4 (2022): 579–599.

[168] L. Chang, Y. Wei, and K. Hashimoto, “Brain-gut-microbiota Axis in Depression: A Historical Overview and Future Directions,” Brain Research Bulletin 182 (2022): 44–56.

[169] M. McDougle, A. de Araujo, A. Singh, et al., “Separate Gut-brain Circuits for Fat and Sugar Reinforcement Combine to Promote Overeating,” Cell Metabolism 36, no. 2 (2024): 393–407. e7.

[170] X. Wang, X. Wen, S. Yuan, and J. Zhang, “Gut-brain Axis in the Pathogenesis of Sepsis-associated Encephalopathy,” Neurobiology of Disease 195 (2024): 106499.

[171] X. Ren, L. Zhang, Y. Zhang, et al., “Insights Gained From Single-Cell Analysis of Immune Cells in the Tumor Microenvironment,” Annual Review of Immunology 39 (2021): 583–609.

[172] B. Lin, Z. Ye, Z. Ye, et al., “Gut Microbiota in Brain Tumors: An Emerging Crucial Player,” CNS Neuroscience & Therapeutics 29, no. Suppl 1 (2023): 84–97.

[173] F. Geng, N. Zhao, and Q. Ren, “Circadian Rhythm, Microglia-mediated Neuroinflammation, and Alzheimer's Disease,” Neuroscience and Biobehavioral Reviews 170 (2025): 106044.

[174] S. Tiwari, V. Atluri, A. Kaushik, A. Yndart, and M. Nair, “Alzheimer's Disease: Pathogenesis, Diagnostics, and Therapeutics,” International Journal of Nanomedicine 14 (2019): 5541–5554.

[175] R. Ossenkoppele, R. van der Kant, and O. Hansson, “Tau Biomarkers in Alzheimer's Disease: Towards Implementation in Clinical Practice and Trials,” Lancet Neurology 21, no. 8 (2022): 726–734.

[176] S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, et al., “Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia,” Nature 541, no. 7638 (2017): 481–487.

[177] M. Arabpour, A. Saghazadeh, and N. Rezaei, “Anti-inflammatory and M2 Macrophage Polarization-promoting Effect of Mesenchymal Stem Cell-derived Exosomes,” International Immunopharmacology 97 (2021): 107823.

[178] M. C. Geloso, L. Zupo, and V. Corvino, “Crosstalk Between Peripheral Inflammation and Brain: Focus on the Responses of Microglia and Astrocytes to Peripheral Challenge,” Neurochemistry International 180 (2024): 105872.

[179] D. Rossi, L. Brambilla, C. F. Valori, et al., “Defective Tumor Necrosis Factor-alpha-dependent Control of Astrocyte Glutamate Release in a Transgenic Mouse Model of Alzheimer disease,” Journal of Biological Chemistry 280, no. 51 (2005): 42088–42096.

[180] Z. Cai, P. F. Qiao, C. Q. Wan, et al., “Role of Blood-Brain Barrier in Alzheimer's Disease,” Journal of Alzheimer's Disease 63, no. 4 (2018): 1223–1234.

[181] E. Zenaro, G. Piacentino, and G. Constantin, “The Blood-brain Barrier in Alzheimer's Disease,” Neurobiology of Disease 107 (2017): 41–56.

[182] L. Zhang, Y. Gai, Y. Liu, et al., “Tau Induces Inflammasome Activation and Microgliosis Through Acetylating NLRP3,” Clinical and Translational Medicine 14, no. 3 (2024): e1623.

[183] J. Yang, L. Wise, and K. I. Fukuchi, “TLR4 Cross-Talk with NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease,” Frontiers in Immunology 11 (2020): 724.

[184] J. Wojcieszak, K. Kuczynska, and J. B. Zawilska, “Role of Chemokines in the Development and Progression of Alzheimer's Disease,” Journal of Molecular Neuroscience 72, no. 9 (2022): 1929–1951.

[185] F. Leng and P. Edison, “Neuroinflammation and Microglial Activation in Alzheimer disease: Where Do We Go From Here?,” Nature Reviews Neurology 17, no. 3 (2021): 157–172.

[186] E. Sun, A. Motolani, L. Campos, and T. Lu, “The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer's Disease,” International Journal of Molecular Sciences 23, no. 16 (2022): 8972.

[187] S. Dewanjee, P. Chakraborty, H. Bhattacharya, et al., “Altered Glucose Metabolism in Alzheimer's Disease: Role of Mitochondrial Dysfunction and Oxidative Stress,” Free Radical Biology and Medicine 193, no. Pt 1 (2022): 134–157.

[188] S. M. Firdous, S. A. Khan, and A. Maity, “Oxidative Stress-mediated Neuroinflammation in Alzheimer's Disease,” Naunyn-Schmiedebergs Archives of Pharmacology 397, no. 11 (2024): 8189–8209.

[189] V. Bhatia and S. Sharma, “Role of Mitochondrial Dysfunction, Oxidative Stress and Autophagy in Progression of Alzheimer's Disease,” Journal of the Neurological Sciences 421 (2021): 117253.

[190] F. M. de Vrij, D. F. Fischer, F. W. van Leeuwen, and E. M. Hol, “Protein Quality Control in Alzheimer's Disease by the Ubiquitin Proteasome System,” Progress in Neurobiology 74, no. 5 (2004): 249–270.

[191] A. Masato, N. Plotegher, D. Boassa, and L. Bubacco, “Impaired Dopamine Metabolism in Parkinson's Disease Pathogenesis,” Molecular Neurodegeneration 14, no. 1 (2019): 35.

[192] R. H. Earls, K. B. Menees, J. Chung, et al., “Intrastriatal Injection of Preformed Alpha-synuclein Fibrils Alters central and Peripheral Immune Cell Profiles in Non-transgenic Mice,” Journal of Neuroinflammation 16, no. 1 (2019): 250.

[193] E. C. Hirsch, T. Breidert, E. Rousselet, et al., “The Role of Glial Reaction and Inflammation in Parkinson's Disease,” Annals of the New York Academy of Sciences 991 (2003): 214–228.

[194] K. Badanjak, S. Fixemer, S. Smajic, A. Skupin, and A. Grunewald, “The Contribution of Microglia to Neuroinflammation in Parkinson's Disease,” International Journal of Molecular Sciences 22, no. 9 (2021): 4676.

[195] E. O'Neill and A. Harkin, “Targeting the Noradrenergic System for Anti-inflammatory and Neuroprotective Effects: Implications for Parkinson's Disease,” Neural Regeneration Research 13, no. 8 (2018): 1332–1337.

[196] A. N. MacMahon Copas, S. F. McComish, J. M. Fletcher, and M. A. Caldwell, “The Pathogenesis of Parkinson's Disease: A Complex Interplay between Astrocytes, Microglia, and T Lymphocytes?,” Frontiers in Neurology 12 (2021): 666737.

[197] L. Iovino, M. E. Tremblay, and L. Civiero, “Glutamate-induced Excitotoxicity in Parkinson's disease: The Role of Glial Cells,” Journal of Pharmacological Sciences 144, no. 3 (2020): 151–164.

[198] H. Park, T. I. Kam, V. L. Dawson, and T. M. Dawson, “alpha-Synuclein Pathology as a Target in Neurodegenerative Diseases,” Nature Reviews Neurology 21, no. 1 (2025): 32–47.

[199] L. Basurco, M. A. Abellanas, L. Ayerra, et al., “Microglia and Astrocyte Activation Is Region-dependent in the Alpha-synuclein Mouse Model of Parkinson's disease,” Glia 71, no. 3 (2023): 571–587.

[200] G. Xiromerisiou, C. Marogianni, I. C. Lampropoulos, et al., “Peripheral Inflammatory Markers TNF-alpha and CCL2 Revisited: Association With Parkinson's Disease Severity,” International Journal of Molecular Sciences 24, no. 1 (2022): 264.

[201] S. Wang, J. Tan, and Q. Zhang, “Cytosolic Escape of Mitochondrial DNA Triggers cGAS-STING Pathway-Dependent Neuronal PANoptosis in Response to Intermittent Hypoxia,” Neurochemical Research 49, no. 8 (2024): 2228–2248.

[202] Y. Li, Y. Xia, S. Yin, et al., “Targeting Microglial Alpha-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease,” Frontiers in Immunology 12 (2021): 719807.

[203] X. Qin, S. Wang, J. Huang, et al., “Rhein Alleviates MPTP-induced Parkinson's Disease by Suppressing Neuroinflammation via MAPK/IkappaB Pathway,” Frontiers in Neuroscience 18 (2024): 1396345.

[204] E. K. Kim and E. J. Choi, “Pathological Roles of MAPK Signaling Pathways in human Diseases,” Biochimica Et Biophysica Acta 1802, no. 4 (2010): 396–405.

[205] I. Ullah, S. Uddin, L. Zhao, X. Wang, and H. Li, “Autophagy and UPS Pathway Contribute to Nicotine-induced Protection Effect in Parkinson's Disease,” Experimental Brain Research 242, no. 4 (2024): 971–986.

[206] T. Nagatsu and M. Sawada, “Cellular and Molecular Mechanisms of Parkinson's Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines,” Cellular and Molecular Neurobiology 26, no. 4–6 (2006): 781–802.

[207] L. Yu, X. Hu, R. Xu, et al., “Piperine Promotes PI3K/AKT/mTOR-mediated Gut-brain Autophagy to Degrade Alpha-Synuclein in Parkinson's Disease Rats,” Journal of Ethnopharmacology 322 (2024): 117628.

[208] D. Soulet and F. Cicchetti, “The Role of Immunity in Huntington's Disease,” Molecular Psychiatry 16, no. 9 (2011): 889–902.

[209] A. Heinzmann, S. Sayah, F. X. Lejeune, et al., “Huntington's Disease With Small CAG Repeat Expansions,” Movement Disorders 38, no. 7 (2023): 1294–1306.

[210] J. Saba, F. L. Couselo, J. Bruno, et al., “Neuroinflammation in Huntington's Disease: A Starring Role for Astrocyte and Microglia,” Current Neuropharmacology 20, no. 6 (2022): 1116–1143.

[211] Y. Huiming, S. Yang, H. Shanshan, T. Beisha, and G. Jifeng, “Microglial Activation in the Pathogenesis of Huntington's Disease,” Frontiers in Aging Neuroscience 9 (2017): 193.

[212] A. Plaza-Zabala, V. Sierra-Torre, and A. Sierra, “Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging,” International Journal of Molecular Sciences 18, no. 3 (2017): 598.

[213] T. Palpagama, A. R. Mills, M. W. Ferguson, et al., “Microglial and Astrocytic Responses in the Human Midcingulate Cortex in Huntington's Disease,” Annals of Neurology 94, no. 5 (2023): 895–910.

[214] K. Qian, X. Jiang, Z. Q. Liu, et al., “Revisiting the Critical Roles of Reactive Astrocytes in Neurodegeneration,” Molecular Psychiatry 28, no. 7 (2023): 2697–2706.

[215] S. J. Tabrizi, M. D. Flower, C. A. Ross, and E. J. Wild, “Huntington Disease: New Insights Into Molecular Pathogenesis and Therapeutic Opportunities,” Nature Reviews Neurology 16, no. 10 (2020): 529–546.

[216] J. M. Goverman, “Regulatory T Cells in Multiple Sclerosis,” New England Journal of Medicine 384, no. 6 (2021): 578–580.

[217] A. Crotti and C. K. Glass, “The Choreography of Neuroinflammation in Huntington's Disease,” Trends in Immunology 36, no. 6 (2015): 364–373.

[218] O. Abu Shelbayeh, T. Arroum, S. Morris, and K. B. Busch, “PGC-1alpha Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response,” Antioxidants (Basel) 12, no. 5 (2023): 1075.

[219] Z. Zhang, H. Zhou, X. Ouyang, et al., “Multifaceted Functions of STING in human Health and Disease: From Molecular Mechanism to Targeted Strategy,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 394.

[220] X. J. Li and S. Li, “Proteasomal Dysfunction in Aging and Huntington Disease,” Neurobiology of Disease 43, no. 1 (2011): 4–8.

[221] E. Bossy-Wetzel, A. Petrilli, and A. B. Knott, “Mutant Huntingtin and Mitochondrial Dysfunction,” Trends in Neuroscience (Tins) 31, no. 12 (2008): 609–616.

[222] W. Kwan, U. Trager, D. Davalos, et al., “Mutant Huntingtin Impairs Immune Cell Migration in Huntington disease,” Journal of Clinical Investigation 122, no. 12 (2012): 4737–4747.

[223] L. S. Ashley, O. Sara, M. Tiziana, et al., “H02 Low Levels of Transforming Growth Factor β1 in Huntington's Disease Peripheral Macrophages and Brain Glial Cells,” Journal of Neurology, Neurosurgery, and Psychiatry (2010).

[224] J. S. Loh, W. Q. Mak, and L. K. S. Tan, “Microbiota–gut–brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 37.

[225] R. E. Rizea, A. D. Corlatescu, H. P. Costin, A. Dumitru, and A. V. Ciurea, “Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances,” International Journal of Molecular Sciences 25, no. 18 (2024): 9966.

[226] E. L. Feldman, S. A. Goutman, S. Petri, et al., “Amyotrophic Lateral Sclerosis,” Lancet 400, no. 10360 (2022): 1363–1380.

[227] H. Ilieva, M. Vullaganti, and J. Kwan, “Advances in Molecular Pathology, Diagnosis, and Treatment of Amyotrophic Lateral Sclerosis,” Bmj 383 (2023): e075037.

[228] B. A. Evangelista, J. V. Ragusa, K. Pellegrino, et al., “ALS-associated TDP-43 Aggregates Drive Innate and Adaptive Immune Cell Activation,” Iscience 28, no. 6 (2025): 112648.

[229] C. Stacchiotti, S. Mazzella di Regnella, M. Cinotti, A. Spalloni, and E. Volpe, “Neuroinflammation and Amyotrophic Lateral Sclerosis: Recent Advances in Anti-Inflammatory Cytokines as Therapeutic Strategies,” International Journal of Molecular Sciences 26, no. 8 (2025): 3854.

[230] S. Krasemann, C. Madore, R. Cialic, et al., “The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases,” Immunity 47, no. 3 (2017): 566–581. e9.

[231] Y. Zhang, D. Ogbu, S. Garrett, Y. Xia, and J. Sun, “Aberrant Enteric Neuromuscular System and Dysbiosis in Amyotrophic Lateral sclerosis,” Gut Microbes 13, no. 1 (2021): 1996848.

[232] F. Provenzano, C. Torazza, T. Bonifacino, G. Bonanno, and M. Milanese, “The Key Role of Astrocytes in Amyotrophic Lateral Sclerosis and Their Commitment to Glutamate Excitotoxicity,” International Journal of Molecular Sciences 24, no. 20 (2023): 15430.

[233] P. S. Mishra, D. K. Dhull, A. Nalini, et al., “Astroglia Acquires a Toxic Neuroinflammatory Role in Response to the Cerebrospinal Fluid From Amyotrophic Lateral sclerosis Patients,” Journal of Neuroinflammation 13, no. 1 (2016): 212.

[234] D. R. Beers and S. H. Appel, “Immune Dysregulation in Amyotrophic Lateral Sclerosis: Mechanisms and Emerging Therapies,” Lancet Neurology 18, no. 2 (2019): 211–220.

[235] T. F. Gendron and L. Petrucelli, “Immunological Drivers of Amyotrophic Lateral Sclerosis,” Science Translational Medicine 15, no. 721 (2023): eadj9332.

[236] M. Calafatti, G. Cocozza, C. Limatola, and S. Garofalo, “Microglial Crosstalk With Astrocytes and Immune Cells in amyotrophic Lateral sclerosis,” Frontiers in Immunology 14 (2023): 1223096.

[237] A. Singh, R. Kukreti, L. Saso, and S. Kukreti, “Oxidative Stress: A Key Modulator in Neurodegenerative Diseases,” Molecules (Basel, Switzerland) 24, no. 8 (2019): 1583.

[238] A. Y. Baev, A. Y. Vinokurov, E. V. Potapova, et al., “Mitochondrial Permeability Transition, Cell Death and Neurodegeneration,” Cells 13 (2024): 7.

[239] R. Q. Yao, C. Ren, Z. F. Xia, and Y. M. Yao, “Organelle-specific Autophagy in Inflammatory Diseases: A Potential Therapeutic Target Underlying the Quality Control of Multiple Organelles,” Autophagy 17, no. 2 (2021): 385–401.

[240] M. M. Klemmensen, S. H. Borrowman, C. Pearce, B. Pyles, and B. Chandra, “Mitochondrial Dysfunction in Neurodegenerative Disorders,” Neurotherapeutics 21, no. 1 (2024): e00292.

[241] J. A. Perez-Cabello, L. Silvera-Carrasco, J. M. Franco, et al., “MAPK/MAK/MRK Overlapping Kinase (MOK) Controls Microglial Inflammatory/Type-I IFN Responses via Brd4 and Is Involved in ALS,” Proceedings of the National Academy of Sciences of of the United States of America 120, no. 28 (2023): e2302143120.

[242] J. M. Frischer, S. D. Weigand, Y. Guo, et al., “Clinical and Pathological Insights Into the Dynamic Nature of the White Matter Multiple Sclerosis Plaque,” Annals of Neurology 78, no. 5 (2015): 710–721.

[243] N. Garg and T. W. Smith, “An Update on Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis,” Brain and Behavior 5, no. 9 (2015): e00362.

[244] R. Marcus, “What Is Multiple Sclerosis?,” Jama 328, no. 20 (2022): 2078.

[245] S. Faissner, J. R. Plemel, R. Gold, and V. W. Yong, “Progressive Multiple Sclerosis: From Pathophysiology to Therapeutic Strategies,” Nature Reviews Drug Discovery 18, no. 12 (2019): 905–922.

[246] S. Rodriguez Murua, M. F. Farez, and F. J. Quintana, “The Immune Response in Multiple Sclerosis,” Annual Review of Pathology 17 (2022): 121–139.

[247] L. Klotz, J. Antel, and T. Kuhlmann, “Inflammation in Multiple Sclerosis: Consequences for Remyelination and Disease Progression,” Nature Reviews Neurology 19, no. 5 (2023): 305–320.

[248] L. Van Kaer, J. L. Postoak, C. Wang, G. Yang, and L. Wu, “Innate, Innate-Like and Adaptive Lymphocytes in the Pathogenesis of MS and EAE,” Cellular & Molecular Immunology 16, no. 6 (2019): 531–539.

[249] C. Prado, A. A. Herrada, D. Hevia, L. G. Goiry, and N. Escobedo, “Role of Innate Immune Cells in Multiple Sclerosis,” Frontiers in Immunology 16 (2025): 1540263.

[250] Y. Li, C. Pereda Serras, J. Blumenfeld, et al., “Cell-type-directed Network-correcting Combination Therapy for Alzheimer's Disease,” Cell 188 (2025): 5516–5534.

[251] J. F. Tuddenham, M. Fujita, E. Lee, et al., “Single-cell Transcriptomic Landscape of the Neuro-immune Compartment in Amyotrophic Lateral Sclerosis Brain and Spinal Cord,” Acta Neuropathologica 150, no. 1 (2025): 10.

[252] C. C. Walton, E. Wang, S. Lee, et al., “A human Neuron alzheimer's disease Model Reveals Barriers to Senolytic Translatability,” Alzheimer's Research & Therapy 17, no. 1 (2025): 176.

[253] S. A. Keil, D. Jansson, M. Braun, and J. J. Iliff, “Glymphatic Dysfunction in Alzheimer's Disease: A Critical Appraisal,” Science 389, no. 6756 (2025): eadv8269.

[254] D. J. Clauw, “Fibromyalgia: A Clinical Review,” Jama 311, no. 15 (2014): 1547–1555.

[255] P. Sarzi-Puttini, V. Giorgi, D. Marotto, and F. Atzeni, “Fibromyalgia: An Update on Clinical Characteristics, Aetiopathogenesis and Treatment,” Nature Reviews Rheumatology 16, no. 11 (2020): 645–660.

[256] D. Clauw, P. Sarzi-Puttini, G. Pellegrino, and Y. Shoenfeld, “Is Fibromyalgia an Autoimmune Disorder?,” Autoimmunity Reviews 23, no. 1 (2024): 103424.

[257] K. Ren and R. Torres, “Role of Interleukin-1beta During Pain and Inflammation,” Brain Research Reviews 60, no. 1 (2009): 57–64.

[258] M. Garcia-Dominguez, “Fibromyalgia and Inflammation: Unrevealing the Connection,” Cells 14, no. 4 (2025): 271.

[259] W. Hauser, J. Ablin, M. A. Fitzcharles, et al., “Fibromyalgia,” Nature Reviews Disease Primers 1 (2015): 15022.

[260] M. Valeria De, P. Ilenia, M. Daniele, C. Francesco, and T. Rosella, “AB0936 Neuropathic Pain in Psoriatic Arthritis: Analysis of Populations Treated With Anti TNF and Anti IL17,” Annals of the Rheumatic Diseases 81 (2022).

[261] C. Macchi, A. Giachi, I. Fichtner, et al., “Mitochondrial Function in Patients Affected With Fibromyalgia Syndrome Is Impaired and Correlates With Disease Severity,” Scientific Reports 14, no. 1 (2024): 30247.

[262] Y. Marino, F. Inferrera, R. D'Amico, et al., “Role of Mitochondrial Dysfunction and Biogenesis in Fibromyalgia Syndrome: Molecular Mechanism in central Nervous System,” Biochimica Et Biophysica Acta-Molecular Basis of Disease 1870, no. 7 (2024): 167301.

[263] L. Liu, Q. Wu, Y. Chen, et al., “Gut Microbiota in Chronic Pain: Novel Insights Into Mechanisms and Promising Therapeutic Strategies,” International Immunopharmacology 115 (2023): 109685.

[264] W. Cai, M. Haddad, R. Haddad, et al., “The Gut Microbiota Promotes Pain in Fibromyalgia,” Neuron 113, no. 13 (2025): 2161–2175. e13.

[265] S. D. Silberstein, “Migraine,” Lancet 363, no. 9406 (2004): 381–391.

[266] A. Charles and P. Pozo-Rosich, “Targeting Calcitonin Gene-related Peptide: A New Era in Migraine Therapy,” Lancet 394, no. 10210 (2019): 1765–1774.

[267] B. J. Rea, A. S. Wattiez, J. S. Waite, et al., “Peripherally Administered Calcitonin Gene-related Peptide Induces Spontaneous Pain in Mice: Implications for Migraine,” Pain 159, no. 11 (2018): 2306–2317.

[268] N. B. Finnerup, R. Kuner, and T. S. Jensen, “Neuropathic Pain: From Mechanisms to Treatment,” Physiological Reviews 101, no. 1 (2021): 259–301.

[269] P. Conti, C. D'Ovidio, C. Conti, et al., “Progression in Migraine: Role of Mast Cells and Pro-inflammatory and Anti-inflammatory Cytokines,” European Journal of Pharmacology 844 (2019): 87–94.

[270] J. Thuraiaiyah, M. Erritzoe-Jervild, H. M. Al-Khazali, H. W. Schytz, and S. Younis, “The Role of Cytokines in Migraine: A Systematic Review,” Cephalalgia 42, no. 14 (2022): 1565–1588.

[271] M. You, N. Chen, Y. Yang, et al., “The Gut Microbiota-brain Axis in Neurological Disorders,” MedComm 5, no. 8 (2024): e656.

[272] W. He, Y. Wang, Y. Zhang, Y. Zhang, and J. Zhou, “The Status of Knowledge on Migraines: The Role of Microglia,” Journal of Neuroimmunology 381 (2023): 578118.

[273] Y. J. Lin, M. Anzaghe, and S. Schulke, “Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis,” Cells 9, no. 4 (2020): 880.

[274] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid Arthritis,” Lancet 388, no. 10055 (2016): 2023–2038.

[275] E. M. Gravallese and G. S. Firestein, “Rheumatoid Arthritis—Common Origins, Divergent Mechanisms,” New England Journal of Medicine 388, no. 6 (2023): 529–542.

[276] M. A. M. van Delft and T. W. J. Huizinga, “An Overview of Autoantibodies in Rheumatoid Arthritis,” Journal of Autoimmunity 110 (2020): 102392.

[277] D. E. Furst and P. Emery, “Rheumatoid Arthritis Pathophysiology: Update on Emerging Cytokine and Cytokine-associated Cell Targets,” Rheumatology 53, no. 9 (2014): 1560–1569.

[278] S. Jang, E. J. Kwon, and J. J. Lee, “Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells,” International Journal of Molecular Sciences 23, no. 2 (2022): 905.

[279] R. G. Rishi, V. K. Sergei, and J. K. Mariana, “Interferon Lambda in Inflammation and Autoimmune Rheumatic Diseases,” Nature Reviews Rheumatology 17 (2021): 349–362.

[280] R. H. Straub, J. Detert, R. Dziurla, et al., “Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis,” Neuroimmunomodulation 24, no. 1 (2017): 11–20.

[281] G. Dashuang, G. Xu, Y. Fan, and W. Qingwen, “Neuro-immune Crosstalk in Rheumatoid Arthritis,” International Journal of Molecular Sciences 23 (2022): 8158.

[282] X. Dai, Y. Fan, and X. Zhao, “Systemic lupus erythematosus: Updated Insights on the Pathogenesis, Diagnosis, Prevention and Therapeutics,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 102.

[283] H. Alberta, I. Talia, M. C. Chiu, and A. Laurent, “Systemic lupus erythematosus,” The Lancet 403, no. 10441 (2024): 2326–2338.

[284] N. P. Duarte-Delgado, G. Vasquez, and B. L. Ortiz-Reyes, “Blood-brain Barrier Disruption and Neuroinflammation as Pathophysiological Mechanisms of the Diffuse Manifestations of Neuropsychiatric Systemic Lupus Erythematosus,” Autoimmunity Reviews 18, no. 4 (2019): 426–432.

[285] N. Dionysis, M. Theodora, P. Alexia, et al., “Microglia Activation in the Presence of Intact Blood–brain Barrier and Disruption of Hippocampal Neurogenesis via IL-6 and IL-18 Mediate Early Diffuse Neuropsychiatric Lupus,” Annals of the Rheumatic Diseases 82 (2023): 646–657.

[286] A. Jacob, B. Hack, E. Chiang, et al., “C5a alters Blood-brain Barrier Integrity in Experimental Lupus,” Faseb Journal 24, no. 6 (2010): 1682–1688.

[287] X. Jingyi, Y. Chunshu, Z. Siyuan, et al., “Disturbance of Neuron–microglia Crosstalk Mediated by GRP78 in Neuropsychiatric Systemic Lupus Erythematosus Mice,” Journal of Neuroinflammation 20 (2023): 150.

[288] L. S. Davis, J. Hutcheson, and C. Mohan, “The Role of Cytokines in the Pathogenesis and Treatment of Systemic Lupus Erythematosus,” Journal of Interferon & Cytokine Research 31, no. 10 (2011): 781–789.

[289] C. E. M. Griffiths, A. W. Armstrong, J. E. Gudjonsson, and J. Barker, “Psoriasis,” Lancet 397, no. 10281 (2021): 1301–1315.

[290] R. B. André, S. S. Itamar, S. Cid Yazigi, A. L. Paulo, and M. B. Isabela, “Psoriasis Severity and Hypothalamic-pituitary-adrenal Axis Function: Results From the CALIPSO Study,” Brazilian Journal of Medical and Biological Research 47 (2014): 1102–1106.

[291] C. B. Eding, A. Ekman, I. Rundquist, and C. Enerbäck, “222 IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis,” Journal of Investigative Dermatology 139 (2019): 1564–1573.

[292] C. Huang, P. Y. Sun, Y. Jiang, et al., “Sensory ASIC3 Channel Exacerbates Psoriatic Inflammation via a Neurogenic Pathway in Female Mice,” Nature Communications 15, no. 1 (2024): 5288.

[293] K. Masahiro and T. Yayoi, “Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis,” Frontiers in Immunology 13 (2022): 941071.

[294] X. Cai, M. Han, F. Lou, et al., “Tenascin C(+) Papillary Fibroblasts Facilitate Neuro-immune Interaction in a Mouse Model of Psoriasis,” Nature Communications 14, no. 1 (2023): 2004.

[295] Y. Bai, Y. Cai, D. Chang, et al., “Immunotherapy for Depression: Recent Insights and Future Targets,” Pharmacology & Therapeutics 257 (2024): 108624.

[296] J. Yao, C. Chen, Y. Guo, et al., “A Review of Research on the Association Between Neuron-Astrocyte Signaling Processes and Depressive Symptoms,” International Journal of Molecular Sciences 24, no. 8 (2023): 6985.

[297] B. Czeh and S. A. Nagy, “Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders,” Frontiers in Molecular Neuroscience 11 (2018): 56.

[298] E. Beurel, M. Toups, and C. B. Nemeroff, “The Bidirectional Relationship of Depression and Inflammation: Double Trouble,” Neuron 107, no. 2 (2020): 234–256.

[299] Z. Yunting, J. W. Maree, V. Gerardo Mendez, et al., “Molecular Evidence for Altered Angiogenesis in Neuroinflammation-Associated Schizophrenia and Bipolar Disorder Implicate an Abnormal Midbrain Blood-Brain Barrier,” Schizophrenia Bulletin 51 (2024): 1146–1161.

[300] M. Maes, A. Vasupanrajit, K. Jirakran, et al., “Simple Dysmood Disorder, a Mild Subtype of Major Depression, Is Not an Inflammatory Condition: Depletion of the Compensatory Immunoregulatory System,” Journal of Affective Disorders 375 (2025): 75–85.

[301] F. F. Brinholi, A. Vasupanrajit, L. O. Semeao, et al., “Increased Malondialdehyde and Nitric Oxide Formation, Lowered Total Radical Trapping Capacity Coupled With Psychological Stressors Are Strongly Associated With the Phenome of First-episode Mild Depression in Undergraduate Students,” Neuroscience 554 (2024): 52–62.

[302] M. Maes, K. Jirakran, A. Vasupanrajit, et al., “Major Depressive Disorder, Neuroticism, Suicidal Behaviors, and Depression Severity Are Associated With Cytokine Networks and Their Intricate Interactions With Metabolic Syndrome,” Journal of Psychosomatic Research 187 (2024): 111951.

[303] W. F. S. Karel, R. M. Mark, S. van Jackelien, et al., “Microglia Transcriptional Profiling in Major Depressive Disorder Shows Inhibition of Cortical Gray Matter Microglia,” Biological Psychiatry 94 (2023): 619–629.

[304] R. Yirmiya, “The Inflammatory Underpinning of Depression: An Historical Perspective,” Brain, Behavior, and Immunity 122 (2024): 433–443.

[305] G. N. Pandey, “Inflammatory and Innate Immune Markers of Neuroprogression in Depressed and Teenage Suicide Brain,” Modern Trends in Pharmacopsychiatry 31 (2017): 79–95.

[306] R. Rahimian, C. Belliveau, R. Chen, and N. Mechawar, “Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder,” Frontiers in Psychiatry 13 (2022): 871997.

[307] G. Rajkowska and C. A. Stockmeier, “Astrocyte Pathology in Major Depressive Disorder: Insights From human Postmortem Brain Tissue,” Current Drug Targets 14, no. 11 (2013): 1225–1236.

[308] Y. Mingming, C. Hao, W. Jing, et al., “The Gut Microbiota–brain Axis in Neurological Disorders,” MedComm 17 (2024): 1225875.

[309] L. Liu, H. Wang, X. Chen, et al., “Gut Microbiota and Its Metabolites in Depression: From Pathogenesis to Treatment,” EBioMedicine 90 (2023): 104527.

[310] S. Fredrik, “American Psychiatric Association,” Diagnostic and Statistical Manual of Mental Disorders. 5th ed. (Washington, DC: American Psychiatric Publishing, 2013): 991. ISBN: 978–0890425558. Price: $122.70, null (2014).

[311] F. W. Elaine, A. M. Vijay, and D. T. Kevin, “Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia,” Annual Review of Clinical Psychology 4, (2008): 189–216.

[312] M. Akira, A. K. Takahiro, and K. Shigenobu, “Cytokines and Schizophrenia: Microglia Hypothesis of Schizophrenia,” Psychiatry and Clinical Neurosciences 63, no. 3 (2009): 257–265.

[313] F. E. Simons, “Advances in H1-antihistamines,” New England Journal of Medicine 351, no. 21 (2004): 2203–2217.

[314] C. Sevoz-Couche, W. Liao, H. Y. C. Foo, et al., “Direct Vagus Nerve Stimulation: A New Tool to Control Allergic Airway Inflammation Through alpha7 Nicotinic Acetylcholine Receptor,” British Journal of Pharmacology 181, no. 13 (2024): 1916–1934.

[315] H. C. Oettgen, “Mast Cells in Food Allergy: Inducing Immediate Reactions and Shaping Long-term Immunity,” Journal of Allergy and Clinical Immunology 151, no. 1 (2023): 21–25.

[316] J. J. Sebastián Domingo, “Irritable Bowel Syndrome,” Medicina Clinica 158, no. 2 (2022): 76–81.

[317] P. J. Jonathan, R. G. Abha, B. Ravi, et al., “Cognitive Behavioral Therapy for Irritable Bowel Syndrome Induces Bidirectional Alterations in the Brain-gut-microbiome Axis Associated With Gastrointestinal Symptom Improvement,” Microbiome 9, no. 1 (2021): 236.

[318] M. D. Gershon, “Nerves, Reflexes, and the Enteric Nervous System: Pathogenesis of the Irritable Bowel Syndrome,” Journal of Clinical Gastroenterology 39, no. 5 Suppl 3 (2005): S184–S193.

[319] K. G. Margolis, M. D. Gershon, and M. Bogunovic, “Cellular Organization of Neuro-immune Interactions in the Gastrointestinal Tract,” Trends in Immunology 37, no. 7 (2016): 487–501.

[320] W. Alison, N. Yvonne, A. Beguelin, and A. F. Leigh, “Dangers of the Chronic Stress Response in the Context of the Microbiota-gut-immune-brain Axis and Mental Health: A Narrative Review,” Frontiers in Immunology 15, (2024): 1365871.

[321] J. Zhai, Y. Li, J. Liu, and C. Dai, “Neuro-immune Interactions: The Bridge Between Inflammatory Bowel Disease and the Gut Microbiota,” Clinical and Translational Medicine 15, no. 5 (2025): e70329.

[322] N. Liu, J. He, Y. Yang, et al., “Enteric GABAergic Neuron-derived Gamma-aminobutyric Acid Initiates Expression of Igfbp7 to Sustain ILC3 Homeostasis,” Nature Immunology 26, no. 3 (2025): 404–415.

[323] A. Wallrapp and I. M. Chiu, “Neuro-immune Interactions in the Intestine,” Annual Review of Immunology 42, no. 1 (2024): 489–519.

[324] J. F. Cryan, K. J. O'Riordan, C. S. M. Cowan, et al., “The Microbiota-Gut-Brain Axis,” Physiological Reviews 99, no. 4 (2019): 1877–2013.

[325] C. Wong and I. M. Chiu, “Neurotransmitter and Neuropeptide Regulation of Gut Immunity,” Current Opinion in Neurobiology 92 (2025): 103036.

[326] D. J. Brinkman, A. S. Ten Hove, M. J. Vervoordeldonk, M. D. Luyer, and W. J. de Jonge, “Neuro-immune Interactions in the Gut and Their Significance for Intestinal Immunity,” Cells 8, no. 7 (2019): 670.

[327] M. A. Wheeler and F. J. Quintana, “The Neuro-immune Connectome in Health and Disease,” Nature 638, no. 8050 (2025): 333–342.

[328] M. Amit, T. Eichwald, A. Roger, et al., “Neuro-immune Cross-talk in Cancer,” Nature Reviews Cancer 25, no. 8 (2025): 573–589.

[329] L. A. Emens, P. J. Romero, A. C. Anderson, et al., “Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision,” Journal for ImmunoTherapy of Cancer 12, no. 6 (2024): e009063.

[330] D. A. Silverman, V. K. Martinez, P. M. Dougherty, et al., “Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk,” Cancer Research 81, no. 6 (2021): 1431–1440.

[331] P. Mauffrey, N. Tchitchek, V. Barroca, et al., “Progenitors From the central Nervous System Drive Neurogenesis in Cancer,” Nature 569, no. 7758 (2019): 672–678.

[332] T. Peng, Y. Guo, Z. Gan, et al., “Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression,” Oxidative Medicine and Cellular Longevity 2022 (2022): 8445093.

[333] D. A. Chudakova, E. M. Samoilova, V. P. Chekhonin, and V. P. Baklaushev, “Improving Efficiency of Direct Pro-Neural Reprogramming: Much-Needed Aid for Neuroregeneration in Spinal Cord Injury,” Cells 12, no. 20 (2023): 2499.

[334] O. K. Dagher, R. D. Schwab, S. K. Brookens, and A. D. Posey, “Advances in Cancer Immunotherapies,” Cell 186, no. 8 (2023): 1814–1814.

[335] C. Galassi, T. A. Chan, I. Vitale, and L. Galluzzi, “The Hallmarks of Cancer Immune Evasion,” Cancer Cell 42, no. 11 (2024): 1825–1863.

[336] D. M. Pardoll, “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer 12, no. 4 (2012): 252–264.

[337] S. Chen, A. Saeed, Q. Liu, et al., “Macrophages in Immunoregulation and Therapeutics,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 207.

[338] Y. Togashi, K. Shitara, and H. Nishikawa, “Regulatory T Cells in Cancer Immunosuppression—implications for Anticancer Therapy,” Nature Reviews Clinical Oncology 16, no. 6 (2019): 356–371.

[339] S. A. Lasser, F. G. Ozbay Kurt, I. Arkhypov, J. Utikal, and V. Umansky, “Myeloid-derived Suppressor Cells in Cancer and Cancer Therapy,” Nature Reviews Clinical Oncology 21, no. 2 (2024): 147–164.

[340] D. Hanahan and M. Monje, “Cancer Hallmarks Intersect With Neuroscience in the Tumor Microenvironment,” Cancer Cell 41, no. 3 (2023): 573–580.

[341] K. R. Taylor and M. Monje, “Neuron-oligodendroglial Interactions in Health and Malignant Disease,” Nature Reviews Neuroscience 24, no. 12 (2023): 733–746.

[342] C. Pan and F. Winkler, “Insights and Opportunities at the Crossroads of Cancer and Neuroscience,” Nature Cell Biology 24, no. 10 (2022): 1454–1460.

[343] Z. Wu, D. Lin, and Y. Li, “Pushing the Frontiers: Tools for Monitoring Neurotransmitters and Neuromodulators,” Nature Reviews Neuroscience 23, no. 5 (2022): 257–274.

[344] B. Channer, S. M. Matt, E. A. Nickoloff-Bybel, et al., “Dopamine, Immunity, and Disease,” Pharmacological Reviews 75, no. 1 (2023): 62–158.

[345] Y. Feng and Y. Lu, “Immunomodulatory Effects of Dopamine in Inflammatory Diseases,” Frontiers in Immunology 12 (2021): 663102.

[346] S. M. Matt and P. J. Gaskill, “Where Is Dopamine and How Do Immune Cells See It?: Dopamine-Mediated Immune Cell Function in Health and Disease,” Journal of Neuroimmune Pharmacology 15, no. 1 (2020): 114–164.

[347] J. Wu, R. Zhang, N. Tang, et al., “Dopamine Inhibits the Function of Gr-1+CD115+ Myeloid-derived Suppressor Cells Through D1-Like Receptors and Enhances Anti-tumor Immunity,” Journal of Leukocyte Biology 97, no. 1 (2015): 191–200.

[348] S. Thomas Broome, K. Louangaphay, and K. A. Keay, “Dopamine: An Immune Transmitter,” Neural Regeneration Research 15, no. 12 (2020): 2173–2185.

[349] Y. Tan, R. Sun, L. Liu, et al., “Tumor Suppressor DRD2 Facilitates M1 Macrophages and Restricts NF-kappaB Signaling to Trigger Pyroptosis in Breast Cancer,” Theranostics 11, no. 11 (2021): 5214–5231.

[350] Q. Liu, R. Zhang, X. Zhang, et al., “Dopamine Improves Chemotherapeutic Efficacy for Pancreatic Cancer by Regulating Macrophage-derived Inflammations,” Cancer Immunology, Immunotherapy 70, no. 8 (2021): 2165–2177.

[351] D. Sato, Y. Hamada, M. Narita, et al., “Tumor Suppression and Improvement in Immune Systems by Specific Activation of Dopamine D1-receptor-expressing Neurons in the Nucleus Accumbens,” Molecular Brain 15, no. 1 (2022): 17.

[352] R. Pacheco, F. Contreras, and M. Zouali, “The Dopaminergic System in Autoimmune Diseases,” Frontiers in Immunology 5 (2014): 117.

[353] W. Zhao, Y. Huang, Z. Liu, et al., “Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway,” PLoS ONE 8, no. 6 (2013): e65860.

[354] Z. Wang, P. Wen, B. Hu, et al., “Dopamine and Dopamine Receptor D1 as a Novel Favourable Biomarker for Hepatocellular Carcinoma,” Cancer Cell International 21, no. 1 (2021): 586.

[355] J. Mikulak, L. Bozzo, A. Roberto, et al., “Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor,” Journal of Immunology 193, no. 6 (2014): 2792–2800.

[356] S. Huang, K. Liu, A. Cheng, et al., “SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses,” Frontiers in Immunology 11 (2020): 558341.

[357] P. Deb, J. Dai, S. Singh, E. Kalyoussef, and P. Fitzgerald-Bocarsly, “Triggering of the cGAS-STING Pathway in Human Plasmacytoid Dendritic Cells Inhibits TLR9-Mediated IFN Production,” Journal of Immunology 205, no. 1 (2020): 223–236.

[358] Y. Wu, Y. Hu, B. Wang, et al., “Dopamine Uses the DRD5-ARRB2-PP2A Signaling Axis to Block the TRAF6-Mediated NF-kappaB Pathway and Suppress Systemic Inflammation,” Molecular Cell 78, no. 1 (2020): 42–56. e6.

[359] B. Marchetti, C. Giachino, C. Tirolo, and M. F. Serapide, ““Reframing” Dopamine Signaling at the Intersection of Glial Networks in the Aged Parkinsonian Brain as Innate Nrf2/Wnt Driver: Therapeutical Implications,” Aging Cell 21, no. 4 (2022): e13575.

[360] M. Levite, “Dopamine and T Cells: Dopamine Receptors and Potent Effects on T Cells, Dopamine Production in T Cells, and Abnormalities in the Dopaminergic System in T Cells in Autoimmune, Neurological and Psychiatric Diseases,” Acta Physiologica (Oxford) 216, no. 1 (2016): 42–89.

[361] L. Xiao, X. Li, C. Fang, J. Yu, and T. Chen, “Neurotransmitters: Promising Immune Modulators in the Tumor Microenvironment,” Frontiers in Immunology 14 (2023): 1118637.

[362] Y. Chen, S. M. Yan, Z. Pu, et al., “Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity,” Cancer Research 82, no. 17 (2022): 3130–3142.

[363] G. Nasi, T. Ahmed, E. Rasini, et al., “Dopamine Inhibits human CD8+ Treg Function Through D(1)-Like Dopaminergic Receptors,” Journal of Neuroimmunology 332 (2019): 233–241.

[364] D. Chakroborty, U. R. Chowdhury, C. Sarkar, et al., “Dopamine Regulates Endothelial Progenitor Cell Mobilization From Mouse Bone Marrow in Tumor Vascularization,” Journal of Clinical Investigation 118, no. 4 (2008): 1380–1389.

[365] Z. N. Zhuang, Y. D. Qi, Q. X. Huang, et al., “Storable Polydopamine Nanoparticles Combined With Bacillus Calmette-Guérin for Photothermal-Immunotherapy of Colorectal Cancer,” Advanced Functional Materials 34, no. 39 (2024).

[366] W. Huang and L. Cao, “Targeting GABA Signalling for Cancer Treatment,” Nature Cell Biology 24, no. 2 (2022): 131–132.

[367] D. Huang, Y. Wang, J. W. Thompson, et al., “Cancer-cell-derived GABA Promotes Beta-catenin-mediated Tumour Growth and Immunosuppression,” Nature Cell Biology 24, no. 2 (2022): 230–241.

[368] A. K. Bhandage and A. Barragan, “GABAergic Signaling by Cells of the Immune System: More the Rule Than the Exception,” Cellular and Molecular Life Sciences 78, no. 15 (2021): 5667–5679.

[369] C. Zhang, A. Quinones, and A. Le, “Metabolic Reservoir Cycles in Cancer,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 180–188.

[370] Z. Hujber, G. Horvath, G. Petovari, et al., “GABA, Glutamine, Glutamate Oxidation and Succinic Semialdehyde Dehydrogenase Expression in human Gliomas,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 271.

[371] G. M. Sizemore, S. T. Sizemore, D. D. Seachrist, and R. A. Keri, “GABA(A) Receptor Pi (GABRP) Stimulates Basal-Like Breast Cancer Cell Migration Through Activation of Extracellular-regulated Kinase 1/2 (ERK1/2),” Journal of Biological Chemistry 289, no. 35 (2014): 24102–24113.

[372] Y. Dong, G. Wang, D. Nie, et al., “Tumor-derived GABA Promotes Lung Cancer Progression by Influencing TAMs Polarization and Neovascularization,” International Immunopharmacology 126 (2024): 111217.

[373] S. H. Jiang, L. L. Zhu, M. Zhang, et al., “GABRP Regulates Chemokine Signalling, Macrophage Recruitment and Tumour Progression in Pancreatic Cancer Through Tuning KCNN4-mediated Ca(2+) Signalling in a GABA-independent Manner,” Gut 68, no. 11 (2019): 1994–2006.

[374] Y. Xia, F. He, X. Wu, et al., “GABA Transporter Sustains IL-1beta Production in Macrophages,” Science Advances 7, no. 15 (2021): eabe9274.

[375] B. Zhang, A. Vogelzang, M. Miyajima, et al., “B Cell-derived GABA Elicits IL-10(+) Macrophages to Limit Anti-tumour Immunity,” Nature 599, no. 7885 (2021): 471–476.

[376] R. Bhat, R. Axtell, A. Mitra, et al., “Inhibitory Role for GABA in Autoimmune Inflammation,” Proceedings of the National Academy of Sciences of of the United States of America 107, no. 6 (2010): 2580–2585.

[377] A. K. Bhandage, Z. Jin, S. V. Korol, et al., “GABA Regulates Release of Inflammatory Cytokines from Peripheral Blood Mononuclear Cells and CD4(+) T Cells and Is Immunosuppressive in Type 1 Diabetes,” EBioMedicine 30 (2018): 283–294.

[378] W. Duan, D. Cao, S. Wang, and J. Cheng, “Serotonin 2A Receptor (5-HT(2A)R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants,” Chemical Reviews 124, no. 1 (2024): 124–163.

[379] X. Wang, S. Q. Fu, X. Yuan, et al., “A GAPDH Serotonylation System Couples CD8(+) T Cell Glycolytic Metabolism to Antitumor Immunity,” Molecular Cell 84, no. 4 (2024): 760–775.

[380] D. Ye, H. Xu, Q. Tang, et al., “The Role of 5-HT Metabolism in Cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876, no. 2 (2021): 188618.

[381] Y. Liu, H. Zhang, Z. Wang, P. Wu, and W. Gong, “5-Hydroxytryptamine1a receptors on Tumour Cells Induce Immune Evasion in Lung Adenocarcinoma Patients With Depression via Autophagy/pSTAT3,” European Journal of Cancer 114 (2019): 8–24.

[382] A. Nocito, F. Dahm, W. Jochum, et al., “Serotonin Regulates Macrophage-mediated Angiogenesis in a Mouse Model of Colon Cancer Allografts,” Cancer Research 68, no. 13 (2008): 5152–5158.

[383] M. de las Casas-Engel, A. Dominguez-Soto, E. Sierra-Filardi, et al., “Serotonin Skews human Macrophage Polarization Through HTR2B and HTR7,” Journal of Immunology 190, no. 5 (2013): 2301–2310.

[384] C. Nieto, I. Rayo, and M. de Las Casas-Engel, “Serotonin (5-HT) Shapes the Macrophage Gene Profile Through the 5-HT(2B)-Dependent Activation of the Aryl Hydrocarbon Receptor,” Journal of Immunology 204, no. 10 (2020): 2808–2817.

[385] T. Ling, Z. Dai, H. Wang, et al., “Serotonylation in Tumor-associated Fibroblasts Contributes to the Tumor-promoting Roles of Serotonin in Colorectal Cancer,” Cancer Letters 600 (2024): 217150.

[386] T. Muller, T. Durk, B. Blumenthal, et al., “5-hydroxytryptamine Modulates Migration, Cytokine and Chemokine Release and T-cell Priming Capacity of Dendritic Cells in Vitro and in Vivo,” PLoS ONE 4, no. 7 (2009): e6453.

[387] M. A. Schneider, L. Heeb, M. M. Beffinger, et al., “Attenuation of Peripheral Serotonin Inhibits Tumor Growth and Enhances Immune Checkpoint Blockade Therapy in Murine Tumor Models,” Science Translational Medicine 13, no. 611 (2021): eabc8188.

[388] S. Leach and K. Suzuki, “Adrenergic Signaling in Circadian Control of Immunity,” Frontiers in Immunology 11 (2020): 1235.

[389] R. Carr 3rd, J. Schilling, J. Song, et al., “beta-arrestin-biased Signaling Through the beta2-adrenergic Receptor Promotes Cardiomyocyte Contraction,” Proceedings of the National Academy of Sciences of of the United States of America 113, no. 28 (2016): E4107–E4116.

[390] G. N. Armaiz-Pena, V. Gonzalez-Villasana, A. S. Nagaraja, et al., “Adrenergic Regulation of Monocyte Chemotactic Protein 1 Leads to Enhanced Macrophage Recruitment and Ovarian Carcinoma Growth,” Oncotarget 6, no. 6 (2015): 4266–4273.

[391] C. Daher, L. Vimeux, R. Stoeva, et al., “Blockade of Beta-Adrenergic Receptors Improves CD8(+) T-cell Priming and Cancer Vaccine Efficacy,” Cancer Immunology Research 7, no. 11 (2019): 1849–1863.

[392] J. Zhu, S. Naulaerts, L. Boudhan, et al., “Tumour Immune Rejection Triggered by Activation of alpha2-adrenergic Receptors,” Nature 618, no. 7965 (2023): 607–615.

[393] D. M. Lamkin, H. Y. Ho, T. H. Ong, et al., “beta-Adrenergic-stimulated Macrophages: Comprehensive Localization in the M1-M2 Spectrum,” Brain, Behavior, and Immunity 57 (2016): 338–346.

[394] N. Kuol, L. Stojanovska, V. Apostolopoulos, and K. Nurgali, “Role of the Nervous System in Cancer Metastasis,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 5.

[395] M. Calvani, G. Bruno, M. Dal Monte, et al., “beta(3) -Adrenoceptor as a Potential Immuno-suppressor Agent in Melanoma,” British Journal of Pharmacology 176, no. 14 (2019): 2509–2524.

[396] M. Calvani, G. Bruno, A. Dabraio, et al., “beta3-Adrenoreceptor Blockade Induces Stem Cells Differentiation in Melanoma Microenvironment,” International Journal of Molecular Sciences 21, no. 4 (2020): 1420.

[397] H. Mohammadpour, C. R. MacDonald, G. Qiao, et al., “beta2 adrenergic Receptor-mediated Signaling Regulates the Immunosuppressive Potential of Myeloid-derived Suppressor Cells,” Journal of Clinical Investigation 129, no. 12 (2019): 5537–5552.

[398] H. Mohammadpour, C. R. MacDonald, P. L. McCarthy, S. I. Abrams, and E. A. Repasky, “beta2-adrenergic Receptor Signaling Regulates Metabolic Pathways Critical to Myeloid-derived Suppressor Cell Function Within the TME,” Cell Reports 37, no. 4 (2021): 109883.

[399] F. Niu, Y. Yu, Z. Li, et al., “Arginase: An Emerging and Promising Therapeutic Target for Cancer Treatment,” Biomedicine & Pharmacotherapy 149 (2022): 112840.

[400] N. Erin, P. J. Boyer, R. H. Bonneau, G. A. Clawson, and D. R. Welch, “Capsaicin-mediated Denervation of Sensory Neurons Promotes Mammary Tumor Metastasis to Lung and Heart,” Anticancer Research 24, no. 2B (2004): 1003–1009.

[401] S. Inbar, E. Neeman, R. Avraham, et al., “Do Stress Responses Promote Leukemia Progression? An Animal Study Suggesting a Role for Epinephrine and Prostaglandin-E2 Through Reduced NK Activity,” PLoS ONE 6, no. 4 (2011): e19246.

[402] A. Nakai, Y. Hayano, F. Furuta, M. Noda, and K. Suzuki, “Control of Lymphocyte Egress From Lymph Nodes Through beta2-adrenergic Receptors,” Journal of Experimental Medicine 211, no. 13 (2014): 2583–2598.

[403] M. A. Cox, “Adrenergic Signaling Dampens T Cell Activity During Chronic Infection and Cancer,” Trends in Neuroscience (Tins) 47, no. 3 (2024): 165–166.

[404] M. J. Bucsek, G. Qiao, C. R. MacDonald, et al., “beta-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8(+) T Cells and Undermines Checkpoint Inhibitor Therapy,” Cancer Research 77, no. 20 (2017): 5639–5651.

[405] A. M. Globig, S. Zhao, J. Roginsky, et al., “The Beta(1)-adrenergic Receptor Links Sympathetic Nerves to T Cell Exhaustion,” Nature 622, no. 7982 (2023): 383–392.

[406] P. Wei, H. Jia, R. Li, et al., “Fluvoxamine Prompts the Antitumor Immune Effect via Inhibiting the PD-L1 Expression on Mice-burdened Colon Tumor,” Cell Biology International 47, no. 2 (2023): 439–450.

[407] A. Kamiya, Y. Hayama, S. Kato, et al., “Retraction Note: Genetic Manipulation of Autonomic Nerve fiber Innervation and Activity and Its Effect on Breast Cancer Progression,” Nature Neuroscience 27, no. 5 (2024): 1020.

[408] L. Wang, H. Liu, X. Chen, et al., “Immune Sculpting of Norepinephrine on MHC-I, B7-1, IDO and B7-H1 Expression and Regulation of Proliferation and Invasion in Pancreatic Carcinoma Cells,” PLoS ONE 7, no. 9 (2012): e45491.

[409] M. A. Cox, C. Bassi, M. E. Saunders, et al., “Beyond Neurotransmission: Acetylcholine in Immunity and Inflammation,” Journal of Internal Medicine 287, no. 2 (2020): 120–133.

[410] J. Chen, I. W. Y. Cheuk, V. Y. Shin, and A. Kwong, “Acetylcholine Receptors: Key Players in Cancer Development,” Surgical Oncology 31 (2019): 46–53.

[411] H. Wang, M. Yu, M. Ochani, et al., “Nicotinic Acetylcholine Receptor alpha7 Subunit Is an Essential Regulator of Inflammation,” Nature 421, no. 6921 (2003): 384–388.

[412] E. de la Torre, L. Davel, M. A. Jasnis, et al., “Muscarinic Receptors Participation in Angiogenic Response Induced by Macrophages From Mammary Adenocarcinoma-bearing Mice,” Breast Cancer Research 7, no. 3 (2005): R345–R352.

[413] J. C. Zimring, L. M. Kapp, M. Yamada, J. Wess, and J. A. Kapp, “Regulation of CD8+ Cytolytic T Lymphocyte Differentiation by a Cholinergic Pathway,” Journal of Neuroimmunology 164, no. 1–2 (2005): 66–75.

[414] M. W. Yang, L. Y. Tao, Y. S. Jiang, et al., “Perineural Invasion Reprograms the Immune Microenvironment Through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma,” Cancer Research 80, no. 10 (2020): 1991–2003.

[415] Z. Dubeykovskaya, Y. Si, X. Chen, et al., “Neural Innervation Stimulates Splenic TFF2 to Arrest Myeloid Cell Expansion and Cancer,” Nature Communications 7 (2016): 10517.

[416] P. Zhu, Z. Jin, G. Kang, et al., “Alpha5 nicotinic Acetylcholine Receptor Mediated Immune Escape of Lung Adenocarcinoma via STAT3/Jab1-PD-L1 Signalling,” Cell Communication and Signaling 20, no. 1 (2022): 121.

[417] N. Kuol, M. Davidson, J. Karakkat, et al., “Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer,” International Journal of Molecular Sciences 24, no. 1 (2022): 596.

[418] Z. Wang, W. Liu, C. Wang, Y. Li, and Z. Ai, “Acetylcholine Promotes the Self-renewal and Immune Escape of CD133+ Thyroid Cancer Cells Through Activation of CD133-Akt Pathway,” Cancer Letters 471 (2020): 116–124.

[419] X. Zhang, G. Liu, Y. N. Zhong, et al., “Structural Basis of Ligand Recognition and Activation of the Histamine Receptor family,” Nature Communications 15, no. 1 (2024): 8296.

[420] L. O'Mahony, M. Akdis, and C. A. Akdis, “Regulation of the Immune Response and Inflammation by Histamine and Histamine Receptors,” Journal of Allergy and Clinical Immunology 128, no. 6 (2011): 1153–1162.

[421] R. K. Martin, S. J. Saleem, L. Folgosa, et al., “Mast Cell Histamine Promotes the Immunoregulatory Activity of Myeloid-derived Suppressor Cells,” Journal of Leukocyte Biology 96, no. 1 (2014): 151–159.

[422] X. D. Yang, W. Ai, S. Asfaha, et al., “Histamine Deficiency Promotes Inflammation-associated Carcinogenesis Through Reduced Myeloid Maturation and Accumulation of CD11b+Ly6G+ Immature Myeloid Cells,” Nature Medicine 17, no. 1 (2011): 87–95.

[423] A. Vila-Leahey, S. A. Oldford, P. A. Marignani, et al., “Ranitidine Modifies Myeloid Cell Populations and Inhibits Breast Tumor Development and Spread in Mice,” Oncoimmunology 5, no. 7 (2016): e1151591.

[424] J. B. Szeberenyi, E. Pallinger, M. Zsinko, et al., “Inhibition of Effects of Endogenously Synthesized Histamine Disturbs in Vitro human Dendritic Cell Differentiation,” Immunology Letters 76, no. 3 (2001): 175–182.

[425] A. Mazzoni, H. A. Young, J. H. Spitzer, A. Visintin, and D. M. Segal, “Histamine Regulates Cytokine Production in Maturing Dendritic Cells, Resulting in Altered T Cell Polarization,” Journal of Clinical Investigation 108, no. 12 (2001): 1865–1873.

[426] E. Tiligada, C. Stefanaki, M. Ennis, and D. Neumann, “Opportunities and Challenges in the Therapeutic Exploitation of Histamine and Histamine Receptor Pharmacology in Inflammation-driven Disorders,” Pharmacology & Therapeutics 263 (2024): 108722.

[427] K. Tomita and S. Okabe, “Exogenous Histamine Stimulates Colorectal Cancer Implant Growth via Immunosuppression in Mice,” Journal of Pharmacological Sciences 97, no. 1 (2005): 116–123.

[428] Y. Zhang, Z. Chen, X. Luo, et al., “Cimetidine Down-regulates Stability of Foxp3 Protein via Stub1 in Treg Cells,” Human Vaccines & Immunotherapeutics 12, no. 10 (2016): 2512–2518.

[429] R. Gutzmer, S. Mommert, M. Gschwandtner, et al., “The Histamine H4 Receptor Is Functionally Expressed on T(H)2 Cells,” Journal of Allergy and Clinical Immunology 123, no. 3 (2009): 619–625.

[430] D. Rogers, A. Vila-Leahey, A. C. Pessoa, et al., “Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated with an Enhanced Antitumor Antibody Response,” Frontiers in Immunology 9 (2018): 1894.

[431] N. A. Mohamad, T. E. Galarza, and G. A. Martin, “H2 antihistamines: May be Useful for Combination Therapies in Cancer?,” Biochemical Pharmacology 223 (2024): 116164.

[432] P. Zhong, K. Nakata, K. Oyama, et al., “Blockade of Histamine Receptor H1 Augments Immune Checkpoint Therapy by Enhancing MHC-I Expression in Pancreatic Cancer Cells,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 138.

[433] P. Hanc, M. A. Messou, J. Ajit, and U. H. von Andrian, “Setting the Tone: Nociceptors as Conductors of Immune Responses,” Trends in Immunology 45, no. 10 (2024): 783–798.

[434] P. Baral, S. Udit, and I. M. Chiu, “Pain and Immunity: Implications for Host Defence,” Nature Reviews Immunology 19, no. 7 (2019): 433–447.

[435] K. Wang, B. Ni, Y. Xie, et al., “Nociceptor Neurons Promote PDAC Progression and Cancer Pain by Interaction With Cancer-associated Fibroblasts and Suppression of Natural Killer Cells,” Cell Research 35, no. 5 (2025): 362–380.

[436] C. Humes, A. Sic, and N. N. Knezevic, “Substance P's Impact on Chronic Pain and Psychiatric Conditions-A Narrative Review,” International Journal of Molecular Sciences 25, no. 11 (2024): 5905.

[437] F. D. Rodriguez and R. Covenas, “Association of Neurokinin-1 Receptor Signaling Pathways With Cancer,” Current Medicinal Chemistry 31, no. 39 (2024): 6460–6486.

[438] X. N. Zhao, Z. Z. Bai, C. H. Li, C. L. Sheng, and H. Y. Li, “The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages,” Drug Design, Development and Therapy 14 (2020): 1943–1952.

[439] A. S. Wattiez, L. P. Sowers, and A. F. Russo, “Calcitonin Gene-related Peptide (CGRP): Role in Migraine Pathophysiology and Therapeutic Targeting,” Expert Opinion on Therapeutic Targets 24, no. 2 (2020): 91–100.

[440] A. F. Russo and D. L. Hay, “CGRP Physiology, Pharmacology, and Therapeutic Targets: Migraine and Beyond,” Physiological Reviews 103, no. 2 (2023): 1565–1644.

[441] L. A. McIlvried, M. A. Atherton, N. L. Horan, T. N. Goch, and N. N. Scheff, “Sensory Neurotransmitter Calcitonin Gene-Related Peptide Modulates Tumor Growth and Lymphocyte Infiltration in Oral Squamous Cell Carcinoma,” Advanced Biology (Weinheim) 6, no. 9 (2022): e2200019.

[442] M. Balood, M. Ahmadi, T. Eichwald, et al., “Nociceptor Neurons Affect Cancer Immunosurveillance,” Nature 611, no. 7935 (2022): 405–412.

[443] L. Li, C. Chen, C. Chiang, et al., “The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review,” International Journal of Biological Sciences 17, no. 8 (2021): 2034–2049.

[444] G. Magni, B. Riboldi, and S. Ceruti, “Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies,” Cells 13, no. 7 (2024): 606.

[445] Y. Liu, X. Shen, Y. Zhang, et al., “Interactions of Glial Cells With Neuronal Synapses, From Astrocytes to Microglia and Oligodendrocyte Lineage Cells,” Glia 71, no. 6 (2023): 1383–1401.

[446] H. R. Peng, Y. K. Zhang, and J. W. Zhou, “The Structure and Function of Glial Networks: Beyond the Neuronal Connections,” Neuroscience Bulletin 39, no. 3 (2023): 531–540.

[447] K. He, H. Wang, R. Huo, S. H. Jiang, and J. Xue, “Schwann Cells and Enteric Glial Cells: Emerging Stars in Colorectal Cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1879, no. 5 (2024): 189160.

[448] L. Sun, S. Chen, and M. Chen, “Schwann Cells in the Tumor Microenvironment: Need More Attention,” Journal of Oncology 2022 (2022): 1058667.

[449] V. Pawolski and M. H. H. Schmidt, “Neuron-Glia Interaction in the Developing and Adult Enteric Nervous System,” Cells 10, no. 1 (2020): 47.

[450] H. Akil, A. Perraud, M. O. Jauberteau, and M. Mathonnet, “Tropomyosin-related Kinase B/Brain Derived-neurotrophic Factor Signaling Pathway as a Potential Therapeutic Target for Colorectal Cancer,” World Journal of Gastroenterology 22, no. 2 (2016): 490–500.

[451] E. Fransen, G. Van Camp, L. Vits, and P. J. Willems, “L1-associated Diseases: Clinical Geneticists Divide, Molecular Geneticists Unite,” Human Molecular Genetics 6, no. 10 (1997): 1625–1632.

[452] Z. Tian, G. Ou, M. Su, et al., “TIMP1 derived From Pancreatic Cancer Cells Stimulates Schwann Cells and Promotes the Occurrence of Perineural Invasion,” Cancer Letters 546 (2022): 215863.

[453] Y. Liu, J. Lin, Z. Yu, et al., “Tumor-associated Schwann Cell Remodeling Under Metabolic Stress via Lactate Sensing Orchestrates Pancreatic Ductal Adenocarcinoma Development,” Cell Metabolism 37, no. 9 (2025): p1907–1925.

[454] Y. Liu, G. Han, K. Feng, et al., “ITGA5-expressing Tumor Cells Interact With Schwann Cells to Drive Nerve Growth Factor-Mediated Immunosuppression of NK Cells,” Molecular Therapy (2025).

[455] Z. Cai, H. Yao, J. Chen, et al., “Schwann Cells in Pancreatic Cancer: Unraveling Their Multifaceted Roles in Tumorigenesis and Neural Interactions,” Cancer Letters 587 (2024): 216689.

[456] T. Huang, Q. Fan, Y. Wang, et al., “Schwann Cell-Derived CCL2 Promotes the Perineural Invasion of Cervical Cancer,” Frontiers in Oncology 10 (2020): 19.

[457] G. V. Shurin, O. Kruglov, F. Ding, et al., “Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth,” Cancer Research 79, no. 10 (2019): 2736–2747.

[458] X. Yao, L. Kong, Y. Qiao, et al., “Schwann Cell-secreted Frizzled-related Protein 1 Dictates Neuroinflammation and Peripheral Nerve Degeneration After Neurotrauma,” Cell Reports Medicine 5, no. 11 (2024): 101791.

[459] B. Zhang, X. Guo, L. Huang, et al., “Tumour-associated Macrophages and Schwann Cells Promote Perineural Invasion via Paracrine Loop in Pancreatic Ductal Adenocarcinoma,” British Journal of Cancer 130, no. 4 (2024): 542–554.

[460] E. M. Oltz, “Neuroimmunology: To Sense and Protect,” Journal of Immunology 204, no. 2 (2020): 239–240.

[461] G. V. Martyn, G. V. Shurin, A. A. Keskinov, Y. L. Bunimovich, and M. R. Shurin, “Schwann Cells Shape the Neuro-immune Environs and Control Cancer Progression,” Cancer Immunology, Immunotherapy 68, no. 11 (2019): 1819–1829.

[462] T. Kawai, M. Ikegawa, D. Ori, and S. Akira, “Decoding Toll-Like Receptors: Recent Insights and Perspectives in Innate Immunity,” Immunity 57, no. 4 (2024): 649–673.

[463] D. Yang, Z. Han, and J. J. Oppenheim, “Alarmins and Immunity,” Immunological Reviews 280, no. 1 (2017): 41–56.

[464] Z. Urban-Wojciuk, M. M. Khan, B. L. Oyler, et al., “The Role of TLRs in Anti-cancer Immunity and Tumor Rejection,” Frontiers in Immunology 10 (2019): 2388.

[465] J. S. Im, N. Tapinos, G. T. Chae, et al., “Expression of CD1d Molecules by human Schwann Cells and Potential Interactions With Immunoregulatory Invariant NK T Cells,” Journal of Immunology 177, no. 8 (2006): 5226–5235.

[466] I. Van Rhijn, L. H. Van den Berg, W. M. Bosboom, H. G. Otten, and T. Logtenberg, “Expression of Accessory Molecules for T-cell Activation in Peripheral Nerve of Patients With CIDP and Vasculitic Neuropathy,” Brain 123, no. Pt 10 (2000): 2020–2029.

[467] K. Murata and M. C. Dalakas, “Expression of the co-stimulatory Molecule BB-1, the Ligands CTLA-4 and CD28 and Their mRNAs in Chronic Inflammatory Demyelinating Polyneuropathy,” Brain 123, no. Pt 8 (2000): 1660–1666.

[468] D. N. Louis, A. Perry, P. Wesseling, et al., “The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary,” Neuro-Oncology 23, no. 8 (2021): 1231–1251.

[469] J. H. Sampson, M. D. Gunn, P. E. Fecci, and D. M. Ashley, “Brain Immunology and Immunotherapy in Brain Tumours,” Nature Reviews Cancer 20, no. 1 (2020): 12–25.

[470] J. Rustenhoven and J. Kipnis, “Brain Borders at the central Stage of Neuroimmunology,” Nature 612, no. 7940 (2022): 417–429.

[471] A. Louveau, T. H. Harris, and J. Kipnis, “Revisiting the Mechanisms of CNS Immune Privilege,” Trends in Immunology 36, no. 10 (2015): 569–577.

[472] M. L. Broekman, S. L. N. Maas, E. R. Abels, et al., “Multidimensional Communication in the Microenvirons of Glioblastoma,” Nature Reviews Neurology 14, no. 8 (2018): 482–495.

[473] M. Weller, M. van den Bent, M. Preusser, et al., “Author Correction: EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood,” Nature Reviews Clinical Oncology 19, no. 5 (2022): 357–358.

[474] M. A. Qazi, P. Vora, C. Venugopal, et al., “Intratumoral Heterogeneity: Pathways to Treatment Resistance and Relapse in human Glioblastoma,” Annals of Oncology 28, no. 7 (2017): 1448–1456.

[475] K. Liu, J. J. Cui, Y. Zhan, et al., “Reprogramming the Tumor Microenvironment by Genome Editing for Precision Cancer Therapy,” Molecular Cancer 21, no. 1 (2022): 98.

[476] M. A. Jayaram and J. J. Phillips, “Role of the Microenvironment in Glioma Pathogenesis,” Annual Review of Pathology 19 (2024): 181–201.

[477] E. Karimi, M. W. Yu, S. M. Maritan, et al., “Single-cell Spatial Immune Landscapes of Primary and Metastatic Brain Tumours,” Nature 614, no. 7948 (2023): 555–563.

[478] D. F. Quail and J. A. Joyce, “The Microenvironmental Landscape of Brain Tumors,” Cancer Cell 31, no. 3 (2017): 326–341.

[479] L. van Vlerken-Ysla, Y. Y. Tyurina, V. E. Kagan, and D. I. Gabrilovich, “Functional States of Myeloid Cells in Cancer,” Cancer Cell 41, no. 3 (2023): 490–504.

[480] Z. Chen, J. L. Ross, and D. Hambardzumyan, “Intravital 2-photon Imaging Reveals Distinct Morphology and Infiltrative Properties of Glioblastoma-associated Macrophages,” Proceedings of the National Academy of Sciences of of the United States of America 116 (2019): 28.

[481] W. Xuan, M. S. Lesniak, C. D. James, A. B. Heimberger, and P. Chen, “Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms,” Trends in Immunology 42, no. 4 (2021): 280–292.

[482] A. Sica and A. Mantovani, “Macrophage Plasticity and Polarization: In Vivo Veritas,” Journal of Clinical Investigation 122, no. 3 (2012): 787–795.

[483] D. Hambardzumyan, D. H. Gutmann, and H. Kettenmann, “The Role of Microglia and Macrophages in Glioma Maintenance and Progression,” Nature Neuroscience 19, no. 1 (2016): 20–27.

[484] T. Hara, R. Chanoch-Myers, N. D. Mathewson, et al., “Interactions Between Cancer Cells and Immune Cells Drive Transitions to Mesenchymal-Like States in Glioblastoma,” Cancer Cell 39, no. 6 (2021): 779–792. e11.

[485] A. Sattiraju, S. Kang, B. Giotti, et al., “Hypoxic Niches Attract and Sequester Tumor-associated Macrophages and Cytotoxic T Cells and Reprogram Them for Immunosuppression,” Immunity 56, no. 8 (2023): 1825–1843. e6.

[486] M. Chen, R. Ren, W. Lin, et al., “Exploring the Oncostatin M (OSM) Feed-forward Signaling of Glioblastoma via STAT3 in Pan-cancer Analysis,” Cancer Cell International 21, no. 1 (2021): 565.

[487] J. Wei, A. Marisetty, B. Schrand, et al., “Osteopontin Mediates Glioblastoma-associated Macrophage Infiltration and Is a Potential Therapeutic Target,” Journal of Clinical Investigation 129, no. 1 (2019): 137–149.

[488] X. Cui, R. T. Tan Morales, W. Qian, et al., “Corrigendum to” Hacking Macrophage-associated Immunosuppression for Regulating Glioblastoma Angiogenesis“ [Biomater. 161 (2018) 164-178],” Biomaterials 287 (2022): 121667.

[489] J. Li, M. M. Kaneda, J. Ma, et al., “PI3Kgamma inhibition Suppresses Microglia/TAM Accumulation in Glioblastoma Microenvironment to Promote Exceptional Temozolomide Response,” Proceedings of the National Academy of Sciences of of the United States of America 118, no. 16 (2021): e2009290118.

[490] L. H. Geraldo, Y. Xu, L. Jacob, et al., “SLIT2/ROBO Signaling in Tumor-associated Microglia and Macrophages Drives Glioblastoma Immunosuppression and Vascular Dysmorphia,” Journal of Clinical Investigation 131, no. 16 (2021).

[491] Y. Yin, S. Qiu, X. Li, et al., “EZH2 suppression in Glioblastoma Shifts Microglia Toward M1 Phenotype in Tumor Microenvironment,” Journal of Neuroinflammation 14, no. 1 (2017): 220.

[492] V. M. Ravi, N. Neidert, P. Will, et al., “T-cell Dysfunction in the Glioblastoma Microenvironment Is Mediated by Myeloid Cells Releasing Interleukin-10,” Nature Communications 13, no. 1 (2022): 925.

[493] A. L. Chang, J. Miska, D. A. Wainwright, et al., “CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells,” Cancer Research 76, no. 19 (2016): 5671–5682.

[494] J. E. Kim, M. A. Patel, A. Mangraviti, et al., “Combination Therapy With Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas,” Clinical Cancer Research 23, no. 1 (2017): 124–136.

[495] C. Yan, Z. Yang, P. Chen, et al., “GPR65 sensing Tumor-derived Lactate Induces HMGB1 Release From TAM via the cAMP/PKA/CREB Pathway to Promote Glioma Progression,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 105.

[496] F. Khan, Y. Lin, H. Ali, et al., “Lactate Dehydrogenase A Regulates Tumor-macrophage Symbiosis to Promote Glioblastoma Progression,” Nature Communications 15, no. 1 (2024): 1987.

[497] I. Vitale, G. Manic, L. M. Coussens, G. Kroemer, and L. Galluzzi, “Macrophages and Metabolism in the Tumor Microenvironment,” Cell Metabolism 30, no. 1 (2019): 36–50.

[498] D. Chen, X. Zhang, Z. Li, and B. Zhu, “Metabolic Regulatory Crosstalk Between Tumor Microenvironment and Tumor-associated Macrophages,” Theranostics 11, no. 3 (2021): 1016–1030.

[499] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-derived Macrophages in Glioblastoma,” Immunity 57, no. 5 (2024): 1105–1123. e8.

[500] D. J. Kloosterman, J. Erbani, M. Boon, et al., “Macrophage-mediated Myelin Recycling Fuels Brain Cancer Malignancy,” Cell 187, no. 19 (2024): 5336–5356. e30.

[501] N. Kamran, M. Chandran, P. R. Lowenstein, and M. G. Castro, “Immature Myeloid Cells in the Tumor Microenvironment: Implications for Immunotherapy,” Clinical Immunology 189 (2018): 34–42.

[502] C. C. Poon, P. M. K. Gordon, K. Liu, et al., “Differential Microglia and Macrophage Profiles in human IDH-mutant and -wild Type Glioblastoma,” Oncotarget 10, no. 33 (2019): 3129–3143.

[503] N. M. Amankulor, Y. Kim, S. Arora, et al., “Mutant IDH1 Regulates the Tumor-associated Immune System in Gliomas,” Genes & Development 31, no. 8 (2017): 774–786.

[504] B. C. Thomas, D. E. Staudt, A. M. Douglas, et al., “CAR T Cell Therapies for Diffuse Midline Glioma,” Trends in Cancer 9, no. 10 (2023): 791–804.

[505] Y. C. Ooi, P. Tran, N. Ung, et al., “The Role of Regulatory T-cells in Glioma Immunology,” Clinical Neurology and Neurosurgery 119 (2014): 125–132.

[506] F. Yasinjan, Y. Xing, H. Geng, et al., “Immunotherapy: A Promising Approach for Glioma Treatment,” Frontiers in Immunology 14 (2023): 1255611.

[507] A. Sarvaria, J. A. Madrigal, and A. Saudemont, “B Cell Regulation in Cancer and Anti-tumor Immunity,” Cellular & Molecular Immunology 14, no. 8 (2017): 662–674.

[508] J. Gao, D. Gu, K. Yang, et al., “Infiltrating Plasma Cells Maintain Glioblastoma Stem Cells Through IgG-Tumor Binding,” Cancer Cell 43, no. 1 (2025): 122–143.

[509] N. Shonka, Y. Piao, M. Gilbert, et al., “Cytokines Associated With Toxicity in the Treatment of Recurrent Glioblastoma With Aflibercept,” Targeted Oncology 8, no. 2 (2013): 117–125.

[510] D. K. Tripathy, L. P. Panda, S. Biswal, and K. Barhwal, “Insights Into the Glioblastoma Tumor Microenvironment: Current and Emerging Therapeutic Approaches,” Frontiers in Pharmacology 15 (2024): 1355242.

[511] D. Hou, S. Wang, B. A. Castro, et al., “Dual alphaVbeta8 Integrin and PD-1 Blockade Overcomes TGFbeta-Mediated B-Cell Suppression to Enhance Anti-Glioma Immunity,” Neuro-Oncology 27, no. 9 (2025): 2355–2369.

[512] H. Lin, C. Liu, A. Hu, et al., “Understanding the Immunosuppressive Microenvironment of Glioma: Mechanistic Insights and Clinical Perspectives,” Journal of Hematology & Oncology 17, no. 1 (2024): 31.

[513] S. Yu, X. Ren, and L. Li, “Myeloid-derived Suppressor Cells in Hematologic Malignancies: Two Sides of the Same Coin,” Experimental Hematology & Oncology 11, no. 1 (2022): 43.

[514] C. Jackson, C. Cherry, S. Bom, et al., “Distinct Myeloid-derived Suppressor Cell Populations in human Glioblastoma,” Science 387, no. 6731 (2025): eabm5214.

[515] Y. L. Su, S. Banerjee, S. V. White, and M. Kortylewski, “STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity,” International Journal of Molecular Sciences 19, no. 6 (2018): 1803.

[516] Y. J. Lin, C. Y. Wu, J. Y. Wu, and M. Lim, “The Role of Myeloid Cells in GBM Immunosuppression,” Frontiers in Immunology 13 (2022): 887781.

[517] I. Golan, L. Rodriguez de la Fuente, and J. A. Costoya, “NK Cell-Based Glioblastoma Immunotherapy,” Cancers (Basel) 10, no. 12 (2018): 2111.

[518] T. Look, R. Sankowski, M. Bouzereau, et al., “CAR T Cells, CAR NK Cells, and CAR Macrophages Exhibit Distinct Traits in Glioma Models but Are Similarly Enhanced When Combined With Cytokines,” Cell Reports Medicine 6, no. 2 (2025): 101931.

[519] R. L. Y. Ho and I. A. W. Ho, “Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade,” Cancers (Basel) 13 (2021): 15.

[520] Y. Guo, Z. Li, L. A. Parsels, et al., “H3K27M Diffuse Midline Glioma Is Homologous Recombination Defective and Sensitized to Radiotherapy and NK Cell-mediated Antitumor Immunity by PARP Inhibition,” BioRxiv (2024).

[521] F. Pasqualetti and S. Zanotti, “Nonrandomised Controlled Trial in Recurrent Glioblastoma Patients: The Promise of Autologous Tumour Lysate-loaded Dendritic Cell Vaccination,” British Journal of Cancer 129 (2023): 6.

[522] Y. Pan, M. Xiong, R. Chen, et al., “Athymic Mice Reveal a Requirement for T-cell-microglia Interactions in Establishing a Microenvironment Supportive of Nf1 Low-grade Glioma Growth,” Genes & Development 32, no. 7–8 (2018): 491–496.

[523] X. Guo, Y. Pan, M. Xiong, et al., “Midkine Activation of CD8(+) T Cells Establishes a Neuron-immune-cancer Axis Responsible for Low-grade Glioma Growth,” Nature Communications 11, no. 1 (2020): 2177.

[524] C. Anastasaki, J. Mo, J. K. Chen, et al., “Neuronal Hyperexcitability Drives central and Peripheral Nervous System Tumor Progression in Models of Neurofibromatosis-1,” Nature Communications 13, no. 1 (2022): 2785.

[525] A. E. Baek, “Neuronal-glioma Cross-talk,” Science Signaling 16, no. 785 (2023): eadi6672.

[526] H. S. Venkatesh, L. T. Tam, P. J. Woo, et al., “Targeting Neuronal Activity-regulated Neuroligin-3 Dependency in High-grade Glioma,” Nature 549, no. 7673 (2017): 533–537.

[527] K. R. Taylor, T. Barron, A. Hui, et al., “Glioma Synapses Recruit Mechanisms of Adaptive Plasticity,” Nature 623, no. 7986 (2023): 366–374.

[528] V. Venkataramani, D. I. Tanev, C. Strahle, et al., “Glutamatergic Synaptic Input to Glioma Cells Drives Brain Tumour Progression,” Nature 573, no. 7775 (2019): 532–538.

[529] S. Dolma, H. J. Selvadurai, X. Lan, et al., “Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells,” Cancer Cell 29, no. 6 (2016): 859–873.

[530] T. Barron, B. Yalcin, M. Su, et al., “GABAergic Neuron-to-glioma Synapses in Diffuse Midline Gliomas,” Nature 639, no. 8056 (2025): 1060–1068.

[531] A. S. Achrol, R. C. Rennert, C. Anders, et al., “Brain Metastases,” Nature Reviews Disease Primers 5, no. 1 (2019): 5.

[532] M. Yousefi, T. Bahrami, A. Salmaninejad, et al., “Lung Cancer-associated Brain Metastasis: Molecular Mechanisms and Therapeutic Options,” Cellular Oncology (Dordrecht) 40, no. 5 (2017): 419–441.

[533] M. R. Strickland, C. Alvarez-Breckenridge, J. F. Gainor, and P. K. Brastianos, “Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity,” Cancer Discovery 12, no. 5 (2022): 1199–1216.

[534] E. Paisana, R. Cascao, M. Alvoeiro, et al., “Immunotherapy in Lung Cancer Brain Metastases,” NPJ Precision Oncology 9, no. 1 (2025): 130.

[535] R. Ramakrishna and R. Rostomily, “Seed, Soil, and Beyond: The Basic Biology of Brain Metastasis,” Surgical Neurology International 4, no. Suppl 4 (2013): S256–S264.

[536] S. Brabletz, H. Schuhwerk, T. Brabletz, and M. P. Stemmler, “Dynamic EMT: A Multi-tool for Tumor Progression,” Embo Journal 40, no. 18 (2021): e108647.

[537] P. T. Ronaldson and T. P. Davis, “Regulation of Blood-brain Barrier Integrity by Microglia in Health and Disease: A Therapeutic Opportunity,” Journal of Cerebral Blood Flow and Metabolism 40, no. 1_suppl (2020): S6–S24.

[538] B. Lacoste, A. Prat, M. Freitas-Andrade, and C. Gu, “The Blood-Brain Barrier: Composition, Properties, and Roles in Brain Health,” Cold Spring Harbor Perspectives in Biology 17, no. 5 (2025): a041422.

[539] S. B. Al Rihani, Y. S. Batarseh, and A. Kaddoumi, “The Blood-Brain Barrier in Health and Disease,” International Journal of Molecular Sciences 24, no. 11 (2023): 648–672.

[540] P. S. Steeg, “The Blood-tumour Barrier in Cancer Biology and Therapy,” Nature Reviews Clinical Oncology 18, no. 11 (2021): 696–714.

[541] N. Izadi, P. Solar, K. Hasanova, et al., “Breaking Boundaries: Role of the Brain Barriers in Metastatic Process,” Fluids Barriers CNS 22, no. 1 (2025): 3.

[542] Y. Hashimoto, C. Greene, A. Munnich, and M. Campbell, “The CLDN5 Gene at the Blood-brain Barrier in Health and Disease,” Fluids Barriers CNS 20, no. 1 (2023): 22.

[543] C. P. Profaci, R. N. Munji, R. S. Pulido, and R. Daneman, “The Blood-brain Barrier in Health and Disease: Important Unanswered Questions,” Journal of Experimental Medicine 217, no. 4 (2020): e20190062.

[544] B. Li, C. Wang, Y. Zhang, et al., “Elevated PLGF Contributes to Small-cell Lung Cancer Brain Metastasis,” Oncogene 32, no. 24 (2013): 2952–2962.

[545] N. Tominaga, N. Kosaka, M. Ono, et al., “Brain Metastatic Cancer Cells Release microRNA-181c-containing Extracellular Vesicles Capable of Destructing Blood-brain Barrier,” Nature Communications 6 (2015): 6716.

[546] S. Tiwary, J. E. Morales, S. C. Kwiatkowski, et al., “Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a,” Scientific Reports 8, no. 1 (2018): 8267.

[547] E. E. Er, M. Valiente, K. Ganesh, et al., “Pericyte-Like Spreading by Disseminated Cancer Cells Activates YAP and MRTF for Metastatic Colonization,” Nature Cell Biology 20, no. 8 (2018): 966–978.

[548] Q. Huang, L. Liu, D. Xiao, et al., “CD44(+) lung Cancer Stem Cell-derived Pericyte-Like Cells Cause Brain Metastases Through GPR124-enhanced Trans-endothelial Migration,” Cancer Cell 41, no. 9 (2023): 1621–1636. e8.

[549] S. Xia, W. Duan, M. Xu, et al., “Mesothelin Promotes Brain Metastasis of Non-small Cell Lung Cancer by Activating MET,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 103.

[550] L. V. Schottlaender, R. Abeti, Z. Jaunmuktane, et al., “Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification,” American Journal of Human Genetics 106, no. 3 (2020): 412–421.

[551] T. T. Lah, M. Novak, and B. Breznik, “Brain Malignancies: Glioblastoma and Brain Metastases,” Seminars in Cancer Biology 60 (2020): 262–273.

[552] D. X. Gan, Y. B. Wang, M. Y. He, et al., “Lung Cancer Cells-Controlled Dkk-1 Production in Brain Metastatic Cascade Drive Microglia to Acquire a Pro-tumorigenic Phenotype,” Frontiers in Cell and Developmental Biology 8 (2020): 591405.

[553] S. L. Foo, K. Sachaphibulkij, C. L. Y. Lee, et al., “Breast Cancer Metastasis to Brain Results in Recruitment and Activation of Microglia Through Annexin-A1/Formyl Peptide Receptor Signaling,” Breast Cancer Research 24, no. 1 (2022): 25.

[554] T. Pukrop, F. Dehghani, H. N. Chuang, et al., “Microglia Promote Colonization of Brain Tissue by Breast Cancer Cells in a Wnt-dependent Way,” Glia 58, no. 12 (2010): 1477–1489.

[555] A. Benbenishty, M. Gadrich, A. Cottarelli, et al., “Prophylactic TLR9 Stimulation Reduces Brain Metastasis Through Microglia Activation,” PLoS Biology 17, no. 3 (2019): e2006859.

[556] R. Blazquez, D. Wlochowitz, A. Wolff, et al., “PI3K: A Master Regulator of Brain Metastasis-promoting Macrophages/Microglia,” Glia 66, no. 11 (2018): 2438–2455.

[557] N. Priego, L. Zhu, C. Monteiro, et al., “Author Correction: STAT3 Labels a Subpopulation of Reactive Astrocytes Required for Brain Metastasis,” Nature Medicine 24, no. 9 (2018): 1481.

[558] L. Sevenich, R. L. Bowman, S. D. Mason, et al., “Analysis of Tumour- and Stroma-supplied Proteolytic Networks Reveals a Brain-metastasis-promoting Role for Cathepsin S,” Nature Cell Biology 16, no. 9 (2014): 876–888.

[559] D. P. Fitzgerald, D. Palmieri, E. Hua, et al., “Reactive Glia Are Recruited by Highly Proliferative Brain Metastases of Breast Cancer and Promote Tumor Cell Colonization,” Clinical & Experimental Metastasis 25, no. 7 (2008): 799–810.

[560] B. P. He, J. J. Wang, X. Zhang, et al., “Differential Reactions of Microglia to Brain Metastasis of Lung Cancer,” Molecular Medicine 12, no. 7–8 (2006): 161–170.

[561] K. T. Evans, K. Blake, A. Longworth, et al., “Microglia Promote Anti-tumour Immunity and Suppress Breast Cancer Brain Metastasis,” Nature Cell Biology 25, no. 12 (2023): 1848–1859.

[562] Y. Zou, F. Ye, Y. Kong, et al., “The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer,” Advanced Science (Weinheim, Germany) 10, no. 5 (2023): e2203699.

[563] D. A. Wainwright, I. V. Balyasnikova, A. L. Chang, et al., “IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival,” Clinical Cancer Research 18, no. 22 (2012): 6110–6121.

[564] I. H. Guldner, Q. Wang, L. Yang, et al., “CNS-Native Myeloid Cells Drive Immune Suppression in the Brain Metastatic Niche Through Cxcl10,” Cell 183, no. 5 (2020): 1234–1248. e25.

[565] E. Louie, X. F. Chen, A. Coomes, et al., “Neurotrophin-3 Modulates Breast Cancer Cells and the Microenvironment to Promote the Growth of Breast Cancer Brain Metastasis,” Oncogene 32, no. 35 (2013): 4064–4077.

[566] K. Kleffman, G. Levinson, I. V. L. Rose, et al., “Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis,” Cancer Discovery 12, no. 5 (2022): 1314–1335.

[567] E. Friebel, K. Kapolou, S. Unger, et al., “Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes,” Cell 181, no. 7 (2020): 1626–1642. e20.

[568] C. Rubio-Perez, E. Planas-Rigol, J. L. Trincado, et al., “Immune Cell Profiling of the Cerebrospinal Fluid Enables the Characterization of the Brain Metastasis Microenvironment,” Nature Communications 12, no. 1 (2021): 1503.

[569] R. Mirzaei and V. W. Yong, “Microglia-T Cell Conversations in Brain Cancer Progression,” Trends in Molecular Medicine 28, no. 11 (2022): 951–963.

[570] L. J. Sudmeier, K. B. Hoang, E. K. Nduom, et al., “Distinct Phenotypic States and Spatial Distribution of CD8(+) T Cell Clonotypes in human Brain Metastases,” Cell Reports Medicine 3, no. 5 (2022): 100620.

[571] A. S. Berghoff, G. Ricken, D. Wilhelm, et al., “Tumor Infiltrating Lymphocytes and PD-L1 Expression in Brain Metastases of Small Cell Lung Cancer (SCLC),” Journal of Neuro-Oncology 130, no. 1 (2016): 19–29.

[572] J. Biermann, J. C. Melms, A. D. Amin, et al., “Dissecting the Treatment-naive Ecosystem of human Melanoma Brain Metastasis,” Cell 185, no. 14 (2022): 2591–2608. e30.

[573] F. Klemm, R. R. Maas, R. L. Bowman, et al., “Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells,” Cell 181, no. 7 (2020): 1643–1660.

[574] J. F. Jacobs, A. J. Idema, K. F. Bol, et al., “Regulatory T Cells and the PD-L1/PD-1 Pathway Mediate Immune Suppression in Malignant human Brain Tumors,” Neuro-Oncology 11, no. 4 (2009): 394–402.

[575] G. Griguolo, A. Tosi, M. V. Dieci, et al., “A Comprehensive Profiling of the Immune Microenvironment of Breast Cancer Brain Metastases,” Neuro-Oncology 24, no. 12 (2022): 2146–2158.

[576] V. Wischnewski, R. R. Maas, P. G. Aruffo, et al., “Phenotypic Diversity of T Cells in human Primary and Metastatic Brain Tumors Revealed by Multiomic Interrogation,” Nature Cancer 4, no. 6 (2023): 908–924.

[577] N. Nayyar, M. A. de Sauvage, J. Chuprin, et al., “CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis,” Clinical Cancer Research 30, no. 2 (2024): 420–435.

[578] I. Smalley, Z. Chen, M. Phadke, et al., “Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases,” Clinical Cancer Research 27, no. 14 (2021): 4109–4125.

[579] L. D. Schreurs, A. F. Vom Stein, S. T. Junger, et al., “The Immune Landscape in Brain Metastasis,” Neuro-Oncology 27, no. 1 (2025): 50–62.

[580] T. W. Hodo, M. T. P. de Aquino, A. Shimamoto, and A. Shanker, “Critical Neurotransmitters in the Neuro-immune Network,” Frontiers in Immunology 11 (2020): 1869.

[581] K. Nakano, T. Higashi, K. Hashimoto, et al., “Antagonizing Dopamine D1-Like Receptor Inhibits Th17 Cell Differentiation: Preventive and Therapeutic Effects on Experimental Autoimmune Encephalomyelitis,” Biochemical and Biophysical Research Communications 373, no. 2 (2008): 286–291.

[582] F. Osorio-Barrios, C. Prado, F. Contreras, and R. Pacheco, “Dopamine Receptor D5 Signaling Plays a Dual Role in Experimental Autoimmune Encephalomyelitis Potentiating Th17-Mediated Immunity and Favoring Suppressive Activity of Regulatory T-Cells,” Frontiers in Cellular Neuroscience 12 (2018): 192.

[583] D. Elgueta, F. Contreras, C. Prado, et al., “Dopamine Receptor D3 Expression Is Altered in CD4(+) T-Cells from Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model,” Frontiers in Immunology 10 (2019): 981.

[584] C. Prado, S. Bernales, and R. Pacheco, “Modulation of T-cell Mediated Immunity by Dopamine Receptor d5,” Endocrine, Metabolic & Immune Disorders-Drug Targets 13, no. 2 (2013): 184–194.

[585] S. Gong, J. Li, L. Ma, et al., “Blockade of Dopamine D1-Like Receptor Signalling Protects Mice Against OVA-induced Acute Asthma by Inhibiting B-cell Activating Transcription Factor Signalling and Th17 Function,” Febs Journal 280, no. 23 (2013): 6262–6273.

[586] R. Arreola, S. Alvarez-Herrera, G. Perez-Sanchez, et al., “Immunomodulatory Effects Mediated by Dopamine,” Journal of Immunology Research 2016 (2016): 3160486.

[587] H. Gonzalez, F. Contreras, C. Prado, et al., “Dopamine Receptor D3 Expressed on CD4+ T Cells Favors Neurodegeneration of Dopaminergic Neurons During Parkinson's Disease,” Journal of Immunology 190, no. 10 (2013): 5048–5056.

[588] P. Barbanti, G. Fabbrini, A. Ricci, et al., “Increased Expression of Dopamine Receptors on Lymphocytes in Parkinson's Disease,” Movement Disorders 14, no. 5 (1999): 764–771.

[589] S. K. Alam, A. Pandit, L. Wang, et al., “Dopamine D(2) Receptor Agonists Abrogate Neuroendocrine Tumour Angiogenesis to Inhibit Chemotherapy-refractory Small Cell Lung Cancer Progression,” Cell Death & Disease 16, no. 1 (2025): 370.

[590] H. Li, J. Li, X. Yu, et al., “The Incidence Rate of Cancer in Patients With Schizophrenia: A Meta-analysis of Cohort Studies,” Schizophrenia Research 195 (2018): 519–528.

[591] Q. Huang, B. Hu, P. Zhang, et al., “Neuroscience of Cancer: Unraveling the Complex Interplay Between the Nervous System, the Tumor and the Tumor Immune Microenvironment,” Molecular Cancer 24, no. 1 (2025): 24.

[592] M. Gallowitsch-Puerta and V. A. Pavlov, “Neuro-immune Interactions via the Cholinergic Anti-inflammatory Pathway,” Life Sciences 80, no. 24–25 (2007): 2325–2329.

[593] W. J. de Jonge and L. Ulloa, “The alpha7 Nicotinic Acetylcholine Receptor as a Pharmacological Target for Inflammation,” British Journal of Pharmacology 151, no. 7 (2007): 915–929.

[594] C. A. Baez-Pagan, M. Delgado-Velez, and J. A. Lasalde-Dominicci, “Activation of the Macrophage alpha7 Nicotinic Acetylcholine Receptor and Control of Inflammation,” Journal of Neuroimmune Pharmacology 10, no. 3 (2015): 468–476.

[595] M. Westman, M. Engstrom, A. I. Catrina, and J. Lampa, “Cell Specific Synovial Expression of Nicotinic Alpha 7 Acetylcholine Receptor in Rheumatoid Arthritis and Psoriatic Arthritis,” Scandinavian Journal of Immunology 70, no. 2 (2009): 136–140.

[596] D. B. Hoover, “Cholinergic Modulation of the Immune System Presents New Approaches for Treating Inflammation,” Pharmacology & Therapeutics 179 (2017): 1–16.

[597] M. A. van Maanen, S. P. Stoof, E. P. van der Zanden, et al., “The alpha7 Nicotinic Acetylcholine Receptor on Fibroblast-Like Synoviocytes and in Synovial Tissue From Rheumatoid arthritis Patients: A Possible Role for a Key Neurotransmitter in Synovial Inflammation,” Arthritis and Rheumatism 60, no. 5 (2009): 1272–1281.

[598] M. A. van Maanen, S. P. Stoof, G. J. Larosa, M. J. Vervoordeldonk, and P. P. Tak, “Role of the Cholinergic Nervous System in Rheumatoid Arthritis: Aggravation of Arthritis in Nicotinic Acetylcholine Receptor alpha7 Subunit Gene Knockout Mice,” Annals of the Rheumatic Diseases 69, no. 9 (2010): 1717–1723.

[599] D. Peterson, M. Van Poppel, W. Boling, et al., “Clinical Safety and Feasibility of a Novel Implantable Neuro-immune Modulation Device for the Treatment of Rheumatoid Arthritis: Initial Results From the Randomized, Double-blind, Sham-controlled RESET-RA Study,” Bioelectronic Medicine 10, no. 1 (2024): 8.

[600] B. Bonaz, “A Novel Neuro-immune Modulation System for the Treatment of Rheumatoid Arthritis,” Bioelectronic Medicine 10, no. 1 (2024): 9.

[601] M. Zouali, “Pharmacological and Electroceutical Targeting of the Cholinergic Anti-Inflammatory Pathway in Autoimmune Diseases,” Pharmaceuticals (Basel) 16, no. 8 (2023): 1089.

[602] H. Liu, X. Zhang, P. Shi, et al., “alpha7 Nicotinic Acetylcholine Receptor: A Key Receptor in the Cholinergic Anti-inflammatory Pathway Exerting an Antidepressant Effect,” Journal of Neuroinflammation 20, no. 1 (2023): 84.

[603] K. Takata, T. Amamiya, H. Mizoguchi, et al., “Alpha7 nicotinic Acetylcholine Receptor-specific Agonist DMXBA (GTS-21) Attenuates Abeta Accumulation Through Suppression of Neuronal Gamma-secretase Activity and Promotion of Microglial Amyloid-beta Phagocytosis and Ameliorates Cognitive Impairment in a Mouse Model of Alzheimer's Disease,” Neurobiology of Aging 62 (2018): 197–209.

[604] J. Kim, H. J. Lee, S. K. Park, et al., “Donepezil Regulates LPS and Abeta-Stimulated Neuroinflammation Through MAPK/NLRP3 Inflammasome/STAT3 Signaling,” International Journal of Molecular Sciences 22, no. 19 (2021): 10637.

[605] W. Pu, Z. Su, J. Wazir, et al., “Protective Effect of alpha7 Nicotinic Acetylcholine Receptor Activation on Experimental Colitis and Its Mechanism,” Molecular Medicine 28, no. 1 (2022): 104.

[606] D. Sharma and J. D. Farrar, “Adrenergic Regulation of Immune Cell Function and Inflammation,” Seminars in Immunopathology 42, no. 6 (2020): 709–717.

[607] S. Thapa and X. Cao, “Nervous Regulation: Beta-2-adrenergic Signaling in Immune Homeostasis, Cancer Immunotherapy, and Autoimmune Diseases,” Cancer Immunology, Immunotherapy 72, no. 8 (2023): 2549–2556.

[608] D. Dorotea and H. Ha, “Activation of Beta(2) Adrenergic Receptor Signaling Modulates Inflammation: A Target Limiting the Progression of Kidney Diseases,” Archives of Pharmacal Research 44, no. 1 (2021): 49–62.

[609] M. C. Takenaka, L. P. Araujo, J. T. Maricato, et al., “Norepinephrine Controls Effector T Cell Differentiation Through beta2-Adrenergic Receptor-Mediated Inhibition of NF-kappaB and AP-1 in Dendritic Cells,” Journal of Immunology 196, no. 2 (2016): 637–644.

[610] M. A. Farooq, I. Ajmal, X. Hui, et al., “beta2-Adrenergic Receptor Mediated Inhibition of T Cell Function and Its Implications for CAR-T Cell Therapy,” International Journal of Molecular Sciences 24, no. 16 (2023):12837.

[611] G. Pongratz and R. H. Straub, “The Sympathetic Nervous Response in Inflammation,” Arthritis Research & Therapy 16, no. 6 (2014): 504.

[612] X. Cheng, T. Lowin, N. Honke, and G. Pongratz, “Components of the Sympathetic Nervous System as Targets to Modulate Inflammation—rheumatoid Arthritis Synovial Fibroblasts as Neuron-Like Cells?,” Journal of Inflammation (London) 20, no. 1 (2023): 9.

[613] P. Harle, G. Pongratz, J. Albrecht, I. H. Tarner, and R. H. Straub, “An Early Sympathetic Nervous System Influence Exacerbates Collagen-induced Arthritis via CD4+CD25+ Cells,” Arthritis and Rheumatism 58, no. 8 (2008): 2347–2355.

[614] P. Harle, D. Mobius, D. J. Carr, J. Scholmerich, and R. H. Straub, “An Opposing Time-dependent Immune-modulating Effect of the Sympathetic Nervous System Conferred by Altering the Cytokine Profile in the Local Lymph Nodes and Spleen of Mice With Type II Collagen-induced Arthritis,” Arthritis and Rheumatism 52, no. 4 (2005): 1305–1313.

[615] L. E. Miller, H. P. Justen, J. Scholmerich, and R. H. Straub, “The Loss of Sympathetic Nerve Fibers in the Synovial Tissue of Patients With Rheumatoid Arthritis Is Accompanied by Increased Norepinephrine Release From Synovial Macrophages,” Faseb Journal 14, no. 13 (2000): 2097–2107.

[616] T. H. Lauten, E. C. Reed, T. Natour, et al., “Beta Adrenergic Signaling as a Therapeutic Target for Autoimmunity,” BioRxiv (2025).

[617] M. A. Flierl, D. Rittirsch, M. Huber-Lang, J. V. Sarma, and P. A. Ward, “Catecholamines-crafty Weapons in the Inflammatory Arsenal of Immune/Inflammatory Cells or Opening pandora's box?,” Molecular Medicine 14, no. 3–4 (2008): 195–204.

[618] A. Koenecke, M. Powell, R. Xiong, et al., “Alpha-1 Adrenergic Receptor Antagonists to Prevent Hyperinflammation and Death From Lower respiratory Tract Infection,” Elife 10 (2021): e61700.

[619] Z. K. Dong, Y. F. Wang, W. P. Li, and W. L. Jin, “Neurobiology of Cancer: Adrenergic Signaling and Drug Repurposing,” Pharmacology & Therapeutics 264 (2024): 108750.

[620] K. Makhlouf, M. Comabella, J. Imitola, H. L. Weiner, and S. J. Khoury, “Oral Salbutamol Decreases IL-12 in Patients With Secondary Progressive Multiple Sclerosis,” Journal of Neuroimmunology 117, no. 1–2 (2001): 156–165.

[621] M. Mokhlesian, F. Heydari, S. J. Boskabadi, et al., “The Effect of Dexmedetomidine on Inflammatory Factors and Clinical Outcomes in Patients with Septic Shock: A Randomized Clinical Trial,” Clinical Therapeutics 47, no. 1 (2025): e9–e17.

[622] L. Yang, J. Lu, Z. Zhao, et al., “Research Progress on Inflammation and Immune Dysregulation in PTSD,” Brain and Behavior 15, no. 6 (2025): e70633.

[623] A. Steptoe, A. Ronaldson, K. Kostich, et al., “The Effect of Beta-adrenergic Blockade on Inflammatory and Cardiovascular Responses to Acute Mental Stress,” Brain, Behavior, and Immunity 70 (2018): 369–375.

[624] Y. Chen, Y. Qian, W. Huang, et al., “Chronic Stress Promotes Tumor Immune Evasion via the Suppression of MHC-I Expression and the Upregulation of PD-L1,” American Journal of Cancer Research 12, no. 11 (2022): 5286–5299.

[625] Q. Geng, L. Li, Z. Shen, et al., “Norepinephrine Inhibits CD8(+) T-cell Infiltration and Function, Inducing Anti-PD-1 mAb Resistance in Lung Adenocarcinoma,” British Journal of Cancer 128, no. 7 (2023): 1223–1235.

[626] J. Zhang, Y. T. Deng, J. Liu, L. Gan, and Y. Jiang, “Role of Transforming Growth Factor-beta1 Pathway in Angiogenesis Induced by Chronic Stress in Colorectal Cancer,” Cancer Biology & Therapy 25, no. 1 (2024): 2366451.

[627] S. W. Cole and A. K. Sood, “Molecular Pathways: Beta-adrenergic Signaling in Cancer,” Clinical Cancer Research 18, no. 5 (2012): 1201–1206.

[628] J. Wrobel, L. , L. Bod, and R. Lengagne, “Propranolol Induces a Favourable Shift of Anti-tumor Immunity in a Murine Spontaneous Model of Melanoma,” Oncotarget 7, no. 47 (2016): 77825–77837.

[629] C. Magnon, S. J. Hall, J. Lin, et al., “Autonomic Nerve Development Contributes to Prostate Cancer Progression,” Science 341, no. 6142 (2013): 1236361.

[630] V. De Giorgi, S. Gandini, M. Grazzini, et al., “Effect of Beta-blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Death,” Mayo Clinic Proceedings 88, no. 11 (2013): 1196–1203.

[631] L. L. Lofling, N. C. Stoer, E. K. Sloan, et al., “beta-blockers and Breast Cancer Survival by Molecular Subtypes: A Population-based Cohort Study and Meta-analysis,” British Journal of Cancer 127, no. 6 (2022): 1086–1096.

[632] S. Gandhi, M. R. Pandey, K. Attwood, et al., “Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity,” Clinical Cancer Research 27, no. 1 (2021): 87–95.

[633] Y. Shan, J. Zhao, Y. Zheng, et al., “Understanding the Function of the GABAergic System and Its Potential Role in Rheumatoid Arthritis,” Frontiers in Immunology 14 (2023): 1114350.

[634] E. L. Sparrow, S. James, K. Hussain, et al., “Activation of GABA(A) Receptors Inhibits T Cell Proliferation,” PLoS ONE 16 (2021): 5.

[635] J. Tian and D. L. Kaufman, “The GABA and GABA-Receptor System in Inflammation, Anti-Tumor Immune Responses, and COVID-19,” Biomedicines 11, no. 2 (2023): 254.

[636] J. Tian, H. Dang, M. Wallner, R. Olsen, and D. L. Kaufman, “Homotaurine, a Safe Blood-brain Barrier Permeable GABA(A)-R-specific Agonist, Ameliorates Disease in Mouse Models of Multiple Sclerosis,” Scientific Reports 8, no. 1 (2018): 16555.

[637] M. P. Serrano-Regal, L. Bayon-Cordero, and J. C. Chara Ventura, “GABA(B) Receptor Agonist baclofen Promotes central Nervous System Remyelination,” Glia 70, no. 12 (2022): 2426–2440.

[638] J. Tian, B. Middleton, V. S. Lee, et al., “GABA(B)-Receptor Agonist-Based Immunotherapy for Type 1 Diabetes in NOD Mice,” Biomedicines 9, no. 1 (2021): 43.

[639] R. G. Feldman, M. Kelly-Hayes, J. P. Conomy, and J. M. Foley, “Baclofen for Spasticity in Multiple Sclerosis. Double-blind Crossover and Three-year Study,” Neurology 28, no. 11 (1978): 1094–1098.

[640] R. Soria-Castro, A. Schcolnik-Cabrera, G. Rodriguez-Lopez, et al., “Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells,” Journal of Immunology Research 2019 (2019): 9678098.

[641] J. G. Meisner, A. D. Marsh, and D. R. Marsh, “Loss of GABAergic Interneurons in Laminae I-III of the Spinal Cord Dorsal Horn Contributes to Reduced GABAergic Tone and Neuropathic Pain After Spinal Cord Injury,” Journal of Neurotrauma 27, no. 4 (2010): 729–737.

[642] Y. S. Gwak and C. E. Hulsebosch, “GABA and central Neuropathic Pain Following Spinal Cord Injury,” Neuropharmacology 60, no. 5 (2011): 799–808.

[643] S. R. Torres, T. S. Frode, G. M. Nardi, et al., “Anti-inflammatory Effects of Peripheral Benzodiazepine Receptor Ligands in Two Mouse Models of Inflammation,” European Journal of Pharmacology 408, no. 2 (2000): 199–211.

[644] B. S. Lee, I. G. Jun, S. H. Kim, and J. Y. Park, “Intrathecal Gabapentin Increases Interleukin-10 Expression and Inhibits Pro-inflammatory Cytokine in a Rat Model of Neuropathic Pain,” Journal of Korean Medical Science 28, no. 2 (2013): 308–314.

[645] A. Imamdin and E. P. C. van der Vorst, “Exploring the Role of Serotonin as an Immune Modulatory Component in Cardiovascular Diseases,” International Journal of Molecular Sciences 24, no. 2 (2023): 1549.

[646] M. Wan, L. Ding, D. Wang, J. Han, and P. Gao, “Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases,” Frontiers in Immunology 11 (2020): 186.

[647] C. D. Nichols and T. P. Foster, “Serotonin, Immune Function, and Psychedelics as Potent Anti-inflammatories,” International Review of Neurobiology 181 (2025): 45–76.

[648] Y. Takenaka, R. Tanaka, K. Kitabatake, et al., “Profiling Differential Effects of 5 Selective Serotonin Reuptake Inhibitors on TLRs-Dependent and -Independent IL-6 Production in Immune Cells Identifies Fluoxetine as Preferred Anti-Inflammatory Drug Candidate,” Frontiers in Pharmacology 13 (2022): 874375.

[649] M. Yin, H. Zhou, J. Li, et al., “The Change of Inflammatory Cytokines After Antidepressant Treatment and Correlation With Depressive Symptoms,” Journal of Psychiatric Research 184 (2025): 418–423.

[650] H. Mojiri-Forushani, E. Khajehali, M. Adelipour, and A. Mohammadi, “Inhibitory Effects of Fluoxetine on the Secretion of Inflammatory Mediators and JAK/STAT3 and JNK/TLR4 Gene Expression,” Molecular Biology Reports 50, no. 3 (2023): 2231–2241.

[651] C. Roumestan, A. Michel, F. Bichon, et al., “Anti-inflammatory Properties of Desipramine and Fluoxetine,” Respiratory Research 8, no. 1 (2007): 35.

[652] F. Nau, B. Yu, D. Martin, and C. D. Nichols, “Serotonin 5-HT2A Receptor Activation Blocks TNF-alpha Mediated Inflammation in Vivo,” PLoS ONE 8, no. 10 (2013): e75426.

[653] Y. Chabbi-Achengli, T. Coman, C. Collet, et al., “Serotonin Is Involved in Autoimmune Arthritis Through Th17 Immunity and Bone Resorption,” American Journal of Pathology 186, no. 4 (2016): 927–937.

[654] L. A. Kiropoulos, V. Rozenblat, and N. Baes, “Inflammatory Proteins Related to Depression in Multiple Sclerosis: A Systematic Review and Meta-analysis,” Brain, Behavior, and Immunity - Health 43 (2025): 100939.

[655] M. U. Mian, M. Afzal, A. A. Butt, et al., “Neuropharmacology of Neuropathic Pain: A Systematic Review,” Cureus 16, no. 9 (2024): e69028.

[656] Y. Zhang and Y. Wang, “The Dual Roles of Serotonin in Antitumor Immunity,” Pharmacological Research 205 (2024): 107255.

[657] G. Ahangari and H. Norioun, “The Dual Role of Dopamine and Serotonin in Cancer Progression and Inflammation: Mechanisms and Therapeutic Potential,” Neuroscience 569 (2025): 184–194.

[658] J. Yan, D. Chen, Z. Ye, et al., “Molecular Mechanisms and Therapeutic Significance of Tryptophan Metabolism and Signaling in Cancer,” Molecular Cancer 23, no. 1 (2024): 241.

[659] K. Jiang, Q. Wang, X. L. Chen, et al., “Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies,” International Journal of Nanomedicine 19 (2024): 8847–8882.

[660] B. Maneglier, G. J. Guillemin, P. Clayette, et al., “Serotonin Decreases HIV-1 Replication in Primary Cultures of human Macrophages Through 5-HT(1A) Receptors,” British Journal of Pharmacology 154 (2008): 1.

[661] A. Waemong, S. Sattayachiti, D. Cheaha, and N. Konthapakdee, “Effects of Oral Administration of Ondansetron, a 5-HT(3) Receptor Antagonist, on Anxiety-related Behaviors and Colonic Hypercontractility in Repeated Stress-induced Mice,” Autonomic Neuroscience 253 (2024): 103178.

[662] C. Zheng, X. W. Zhou, and J. Z. Wang, “The Dual Roles of Cytokines in Alzheimer's Disease: Update on Interleukins, TNF-alpha, TGF-beta and IFN-gamma,” Translational Neurodegeneration 5 (2016): 7.

[663] N. Torres-Acosta, J. H. O'Keefe, E. L. O'Keefe, R. Isaacson, and G. Small, “Therapeutic Potential of TNF-alpha Inhibition for Alzheimer's Disease Prevention,” Journal of Alzheimer's Disease 78, no. 2 (2020): 619–626.

[664] H. S. Kwon and S. H. Koh, “Neuroinflammation in Neurodegenerative Disorders: The Roles of Microglia and Astrocytes,” Translational Neurodegeneration 9, no. 1 (2020): 42.

[665] N. Gonzalez Caldito, “Role of Tumor Necrosis Factor-alpha in the central Nervous System: A Focus on Autoimmune Disorders,” Frontiers in Immunology 14 (2023): 1213448.

[666] M. C. Leal, J. C. Casabona, M. Puntel, and F. J. Pitossi, “Interleukin-1beta and Tumor Necrosis Factor-alpha: Reliable Targets for Protective Therapies in Parkinson's Disease?,” Frontiers in Cellular Neuroscience 7 (2013): 53.

[667] E. Roohi, N. Jaafari, and F. Hashemian, “On Inflammatory Hypothesis of Depression: What Is the Role of IL-6 in the Middle of the Chaos?,” Journal of Neuroinflammation 18, no. 1 (2021): 45.

[668] D. Lobo-Silva, G. M. Carriche, A. G. Castro, S. Roque, and M. Saraiva, “Balancing the Immune Response in the Brain: IL-10 and Its Regulation,” Journal of Neuroinflammation 13, no. 1 (2016): 297.

[669] H. Zhao, J. Wei, and J. Sun, “Roles of TGF-beta Signaling Pathway in Tumor Microenvirionment and Cancer Therapy,” International Immunopharmacology 89, no. Pt B (2020): 107101.

[670] A. Tylutka, P. Zabinski, L. Walas, and A. Zembron-Lacny, “Neuroinflammation as a Link in Parkinson's and Alzheimer's Diseases: A Systematic Review and Meta-Analysis,” Aging and Disease 16, no. 6 (2024): 3584–3600.

[671] Y. Cantero-Fortiz and M. Boada, “The Role of Inflammation in Neurological Disorders: A Brief Overview of multiple Sclerosis, Alzheimer's, and Parkinson's Disease,” Frontiers in Neurology 15 (2024): 1439125.

[672] P. Kamila, K. Kar, S. Chowdhury, et al., “Effect of Neuroinflammation on the Progression of Alzheimer's Disease and Its Significant Ramifications for Novel Anti-inflammatory Treatments,” IBRO Neuroscience Reports 18 (2025): 771–782.

[673] E. L. Tobinick and H. Gross, “Rapid Cognitive Improvement in Alzheimer's Disease Following Perispinal Etanercept Administration,” Journal of Neuroinflammation 5 (2008): 2.

[674] J. Butchart, L. Brook, V. Hopkins, et al., “Etanercept in Alzheimer Disease: A Randomized, Placebo-controlled, Double-blind, Phase 2 Trial,” Neurology 84, no. 21 (2015): 2161–2168.

[675] W. Ou, J. Yang, J. Simanauskaite, et al., “Biologic TNF-alpha Inhibitors Reduce Microgliosis, Neuronal Loss, and Tau Phosphorylation in a Transgenic Mouse Model of Tauopathy,” Journal of Neuroinflammation 18, no. 1 (2021): 312.

[676] M. G. Tansey, R. L. Wallings, M. C. Houser, et al., “Inflammation and Immune Dysfunction in Parkinson disease,” Nature Reviews Immunology 22, no. 11 (2022): 657–673.

[677] T. W. Liu, C. M. Chen, and K. H. Chang, “Biomarker of Neuroinflammation in Parkinson's Disease,” International Journal of Molecular Sciences 23, no. 8 (2022): 4148.

[678] X. Ye, D. Ren, Q. Chen, et al., “Resolution of Inflammation During Rheumatoid Arthritis,” Frontiers in Cell and Developmental Biology 13 (2025): 1556359.

[679] Q. Y. Su, J. Luo, Y. Zhang, et al., “Efficacy and Safety of Current Therapies for Difficult-to-treat Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis,” Journal of Translational Medicine 22, no. 1 (2024): 795.

[680] S. Parisi, M. C. Ditto, F. Ghellere, et al., “Update on tocilizumab in Rheumatoid Arthritis: A Narrative Review,” Frontiers in Immunology 16 (2025): 1470488.

[681] K. Wang, H. Luo, L. Liu, et al., “Blockade of IL-1 family Cytokines in the Treatment of Rheumatoid Arthritis,” Frontiers in Pharmacology 16 (2025): 1577628.

[682] A. Kunchok, A. J. Aksamit, J. M. Davis 3rd, et al., “Association between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events,” JAMA Neurology 77, no. 8 (2020): 937–946.

[683] K. A. Zervides, E. Grenmyr, S. Janelidze, et al., “The Impact of Disease Activity and Interferon-alpha on the Nervous System in Systemic lupus erythematosus,” Arthritis Research & Therapy 27, no. 1 (2025): 60.

[684] M. F. Loncharich and I. Robertson, “Anifrolumab in Systemic Lupus Erythematosus,” Drugs of Today (Barcelona, Spain: 1998) 59, no. 2 (2023): 53–61.

[685] E. D. Deeks, “Anifrolumab: First Approval,” Drugs 81, no. 15 (2021): 1795–1802.

[686] K. Findeisen, E. Guymer, and G. Littlejohn, “Neuroinflammatory and Immunological Aspects of Fibromyalgia,” Brain Sciences 15, no. 2 (2025): 206.

[687] A. Ebersberger and H. G. Schaible, “Do Cytokines Play a Role in the Transition From Acute to Chronic Musculoskeletal Pain?,” Pharmacological Research 212 (2025): 107585.

[688] E. Gabay, G. Wolf, Y. Shavit, R. Yirmiya, and M. Tal, “Chronic Blockade of Interleukin-1 (IL-1) Prevents and Attenuates Neuropathic Pain Behavior and Spontaneous Ectopic Neuronal Activity Following Nerve Injury,” European Journal of Pain (London, England) 15, no. 3 (2011): 242–248.

[689] M. E. Roerink, S. J. H. Bredie, M. Heijnen, et al., “Cytokine Inhibition in Patients with Chronic Fatigue Syndrome: A Randomized Trial,” Annals of Internal Medicine 166, no. 8 (2017): 557–564.

[690] N. Elbakary, N. Al-Khuzaei, T. Hussain, et al., “Inflammatory Biomarkers as Predictors for Unlocking Antidepressant Efficacy: Assessing Predictive Value and Risk Stratification in Major Depressive Disorder in a Prospective Longitudinal Study,” Journal of Affective Disorders 387 (2025): 119545.

[691] C. N. Schmitz, G. Sammer, E. Neumann, et al., “Functional Resting state Connectivity Is Differentially Associated With IL-6 and TNF-alpha in Depression and in Healthy Controls,” Scientific Reports 15, no. 1 (2025): 1769.

[692] W. Jiao, J. Lin, Y. Deng, et al., “The Immunological Perspective of Major Depressive Disorder: Unveiling the Interactions Between central and Peripheral Immune Mechanisms,” Journal of Neuroinflammation 22, no. 1 (2025): 10.

[693] C. L. Raison, R. E. Rutherford, B. J. Woolwine, et al., “A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist infliximab for Treatment-resistant Depression: The Role of Baseline Inflammatory Biomarkers,” JAMA Psychiatry 70, no. 1 (2013): 31–41.

[694] M. M. Rizk, L. Bolton, F. Cathomas, et al., “Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies,” Journal of Clinical Psychiatry 85, no. 3 (2024): 23nr15243.

[695] J. M. Knight, E. S. Costanzo, S. Singh, et al., “The IL-6 Antagonist Tocilizumab Is Associated With Worse Depression and Related Symptoms in the Medically Ill,” Translational Psychiatry 11, no. 1 (2021): 58.

[696] Y. T. Li and X. Zeng, “Circulating Inflammatory Cytokines Influencing Schizophrenia: A Mendelian Randomization Study,” Frontiers in Psychiatry 15 (2024): 1417213.

[697] R. R. Girgis, A. Ciarleglio, T. Choo, et al., “A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia,” Neuropsychopharmacology 43, no. 6 (2018): 1317–1323.

[698] T. Miyaoka, R. Yasukawa, H. Yasuda, et al., “Minocycline as Adjunctive Therapy for Schizophrenia: An Open-label Study,” Clinical Neuropharmacology 31, no. 5 (2008): 287–292.

[699] H. Gong, W. J. Su, S. L. Deng, et al., “Anti-inflammatory Interventions for the Treatment and Prevention of Depression Among Older Adults: A Systematic Review and Meta-analysis,” Translational Psychiatry 15, no. 1 (2025): 114.

[700] J. Wen, Y. Li, W. Deng, and Z. Li, “Central Nervous System and Immune Cells Interactions in Cancer: Unveiling New Therapeutic Avenues,” Frontiers in Immunology 16 (2025): 1528363.

[701] T. A. Mace, R. Shakya, J. R. Pitarresi, et al., “IL-6 and PD-L1 Antibody Blockade Combination Therapy Reduces Tumour Progression in Murine Models of Pancreatic Cancer,” Gut 67, no. 2 (2018): 320–332.

[702] I. M. Chen, J. S. Johansen, S. Theile, et al., “Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine with or without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia,” Journal of Clinical Oncology 43, no. 18 (2025): 2107–2118.

[703] W. L. Wang, Y. H. Hao, X. Pang, and Y. L. Tang, “Cancer Pain: Molecular Mechanisms and Management,” Molecular Biomedicine 6, no. 1 (2025): 45.

[704] I. H. Chowdhury, S. Rahman, Y. J. Afroze, and S. T. Shovah, “IUPHAR ECR Review: Cancer-related Anorexia-cachexia in Cancer Patients: Pathophysiology and Treatment,” Pharmacological Research 203 (2024): 107129.

[705] L. Capuron, J. F. Gumnick, D. L. Musselman, et al., “Neurobehavioral Effects of Interferon-alpha in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions,” Neuropsychopharmacology 26, no. 5 (2002): 643–652.

[706] P. Richter, L. A. Macovei, C. Rezus, et al., “IL-10 in Systemic Lupus Erythematosus: Balancing Immunoregulation and Autoimmunity,” International Journal of Molecular Sciences 26, no. 7 (2025): 3290.

[707] I. Sankaranarayanan, D. Tavares-Ferreira, J. M. Mwirigi, et al., “Inducible co-stimulatory Molecule (ICOS) Alleviates Paclitaxel-induced Neuropathic Pain via an IL-10-mediated Mechanism in Female Mice,” Journal of Neuroinflammation 20, no. 1 (2023): 32.

[708] E. D. Milligan, K. R. Penzkover, R. G. Soderquist, and M. J. Mahoney, “Spinal Interleukin-10 Therapy to Treat Peripheral Neuropathic Pain,” Neuromodulation 15, no. 6 (2012): 520–526. discussion 526.

[709] M. Mohammadian, E. J. Morrissey, P. C. Knight, et al., “Investigating the Potential of Minocycline in Reducing Brain Inflammation in Chronic Low Back Pain: A Randomized, Placebo-controlled Mechanistic Clinical Trial,” Pain 166, no. 9 (2025): 2044–2053.

[710] S. S. Widodo, M. Dinevska, L. M. Furst, S. S. Stylli, and T. Mantamadiotis, “IL-10 in Glioma,” British Journal of Cancer 125, no. 11 (2021): 1466–1476.

[711] D. Lorizio, M. Silginer, J. Friesen, et al., “Simultaneous TGF-beta and GITR Pathway Modulation Promotes Anti-tumor Immunity in Glioma,” Cancer Immunology, Immunotherapy 74, no. 8 (2025): 254.

[712] A. Papachristodoulou, M. Silginer, M. Weller, et al., “Therapeutic Targeting of TGFbeta Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas,” Clinical Cancer Research 25, no. 23 (2019): 7189–7201.

[713] U. Bogdahn, P. Hau, G. Stockhammer, et al., “Targeted Therapy for High-grade Glioma With the TGF-beta2 Inhibitor Trabedersen: Results of a Randomized and Controlled Phase IIb Study,” Neuro-Oncology 13, no. 1 (2011): 132–142.

[714] J. Han, C. A. Alvarez-Breckenridge, Q. E. Wang, and J. Yu, “TGF-beta Signaling and Its Targeting for Glioma Treatment,” American Journal of Cancer Research 5, no. 3 (2015): 945–955.

[715] N. Li, J. L. Rodriguez, Y. Yin, et al., “Armored Bicistronic CAR T Cells With Dominant-negative TGF-beta Receptor II to Overcome Resistance in Glioblastoma,” Molecular Therapy 32, no. 10 (2024): 3522–3538.

[716] L. Liu, S. Lou, D. Fu, et al., “Neuro-immune Interactions: Exploring the Anti-inflammatory Role of the Vagus Nerve,” International Immunopharmacology 159 (2025): 114941.

[717] Y. T. Fang, Y. T. Lin, W. L. Tseng, et al., “Neuroimmunomodulation of Vagus Nerve Stimulation and the Therapeutic Implications,” Frontiers in Aging Neuroscience 15 (2023): 1173987.

[718] H. Jin, M. Li, E. Jeong, F. Castro-Martinez, and C. S. Zuker, “A Body-brain Circuit That Regulates Body Inflammatory Responses,” Nature 630, no. 8017 (2024): 695–703.

[719] F. J. Liu, J. Wu, L. J. Gong, H. S. Yang, and H. Chen, “Non-invasive Vagus Nerve Stimulation in Anti-inflammatory Therapy: Mechanistic Insights and Future Perspectives,” Frontiers in Neuroscience 18 (2024): 1490300.

[720] D. R. Hulsey, J. R. Riley, K. W. Loerwald, et al., “Parametric Characterization of Neural Activity in the Locus Coeruleus in Response to Vagus Nerve Stimulation,” Experimental Neurology 289 (2017): 21–30.

[721] Z. Wu, X. Zhang, T. Cai, et al., “Transcutaneous Auricular Vagus Nerve Stimulation Reduces Cytokine Production in Sepsis: An Open Double-blind, Sham-controlled, Pilot Study,” Brain Stimulation 16, no. 2 (2023): 507–514.

[722] M. C. Genovese, N. B. Gaylis, D. Sikes, et al., “Safety and Efficacy of Neurostimulation With a Miniaturised Vagus Nerve Stimulation Device in Patients With Multidrug-refractory Rheumatoid Arthritis: A Two-stage Multicentre, Randomised Pilot Study,” The Lancet Rheumatology 2, no. 9 (2020): e527–e538.

[723] B. Bonaz, V. Sinniger, and S. Pellissier, “The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract,” Frontiers in Immunology 8 (2017): 1452.

[724] B. Sahn, K. Pascuma, N. Kohn, K. J. Tracey, and J. F. Markowitz, “Transcutaneous Auricular Vagus Nerve Stimulation Attenuates Inflammatory Bowel Disease in Children: A Proof-of-concept Clinical Trial,” Bioelectronic Medicine 9, no. 1 (2023): 23.

[725] E. Chan and A. R. Mani, “Assessing the Therapeutic Potential of Vagus Nerve Stimulation in Autoimmune Diseases: A Systematic Review,” Physiological Reports 13, no. 3 (2025): e70230.

[726] M. Vargas-Caballero, H. Warming, R. Walker, et al., “Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review,” Frontiers in Human Neuroscience 16 (2022): 866434.

[727] R. Kamoga, G. Z. Rukundo, S. Kalungi, et al., “Vagus Nerve Stimulation in Dementia: A Scoping Review of Clinical and Pre-clinical Studies,” AIMS Neuroscience 11, no. 3 (2024): 398–420.

[728] Z. Chen and K. Liu, “Mechanism and Applications of Vagus Nerve Stimulation,” Current Issues in Molecular Biology 47, no. 2 (2025): 122.

[729] I. Pastis, M. G. Santos, and A. Paruchuri, “Exploring the Role of Inflammation in Major Depressive Disorder: Beyond the Monoamine Hypothesis,” Frontiers in Behavioral Neuroscience 17 (2023): 1282242.

[730] P. Lesperance, V. Desbeaumes Jodoin, D. Drouin, et al., “Vagus Nerve Stimulation Modulates Inflammation in Treatment-Resistant Depression Patients: A Pilot Study,” International Journal of Molecular Sciences 25, no. 5 (2024): 2679.

[731] E. Kavakbasi, E. Van Assche, K. Schwarte, C. Hohoff, and B. T. Baune, “Long-Term Immunomodulatory Impact of VNS on Peripheral Cytokine Profiles and Its Relationship With Clinical Response in Difficult-to-Treat Depression (DTD),” International Journal of Molecular Sciences 25, no. 8 (2024): 4196.

[732] A. H. Young, M. F. Juruena, R. De Zwaef, and K. Demyttenaere, “Vagus Nerve Stimulation as Adjunctive Therapy in Patients With Difficult-to-treat Depression (RESTORE-LIFE): Study Protocol Design and Rationale of a Real-world Post-market Study,” BMC Psychiatry [Electronic Resource] 20, no. 1 (2020): 471.

[733] F. R. Carreno and A. Frazer, “Vagal Nerve Stimulation for Treatment-Resistant Depression,” Neurotherapeutics 14, no. 3 (2017): 716–727.

[734] W. B. Huang, H. Z. Lai, J. Long, et al., “Vagal Nerve Activity and Cancer Prognosis: A Systematic Review and Meta-analysis,” BMC Cancer 25, no. 1 (2025): 579.

[735] M. De Couck, R. Caers, D. Spiegel, and Y. Gidron, “The Role of the Vagus Nerve in Cancer Prognosis: A Systematic and a Comprehensive Review,” Journal of Oncology 2018 (2018): 1236787.

[736] S. Brem, “Vagus Nerve Stimulation: Novel Concept for the Treatment of Glioblastoma and Solid Cancers by Cytokine (interleukin-6) Reduction, Attenuating the SASP, Enhancing Tumor Immunity,” Brain, Behavior, and Immunity - Health 42 (2024): 100859.

[737] C. W. Austelle, S. S. Cox, K. E. Wills, and B. W. Badran, “Vagus Nerve Stimulation (VNS): Recent Advances and Future Directions,” Clinical Autonomic Research 34, no. 6 (2024): 529–547.

[738] J. S. Kim, D. Y. Kim, H. J. Jo, et al., “Effect of Long-Term Treatment With Vagus Nerve Stimulation on Mood and Quality of Life in Korean Patients With Drug-Resistant Epilepsy,” Journal of Clinical Neurology 17, no. 3 (2021): 385–392.

[739] G. D'Haens, M. Eberhardson, Z. Cabrijan, et al., “Neuro-immune Modulation through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study,” Journal of Crohn's and Colitis 17, no. 12 (2023): 1897–1909.

[740] C. R. Conway, S. T. Aaronson, H. A. Sackeim, et al., “Vagus Nerve Stimulation in Treatment-resistant Depression: A One-year, Randomized, Sham-controlled Trial,” Brain Stimulation 18, no. 3 (2025): 676–689.

[741] E. Reijmen, S. De Mey, H. Van Damme, et al., “Transcutaneous Vagal Nerve Stimulation Alone or in Combination with Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes but Fails to Suppress Tumor Growth,” Frontiers in Immunology 12 (2021): 772555.

[742] T. Wang, T. Nonomura, T. H. Lan, and Y. Zhou, “Optogenetic Engineering for Ion Channel Modulation,” Current Opinion in Chemical Biology 85 (2025): 102569.

[743] S. Li, J. Zhang, J. Li, et al., “Optogenetics and Chemogenetics: Key Tools for Modulating Neural Circuits in Rodent Models of Depression,” Frontiers in Neural Circuits 19 (2025): 1516839.

[744] S. Weiler, M. Velez-Fort, and T. W. Margrie, “Overcoming off-target Optical Stimulation-evoked Cortical Activity in the Mouse Brain in Vivo,” Iscience 27, no. 11 (2024): 111152.

[745] S. Rodriguez-Rozada, J. Wietek, F. Tenedini, et al., “Aion Is a Bistable Anion-conducting Channelrhodopsin That Provides Temporally Extended and Reversible Neuronal Silencing,” Communications Biology 5, no. 1 (2022): 687.

[746] R. G. Fernandez Lahore, N. P. Pampaloni, E. Schiewer, et al., “Calcium-permeable Channelrhodopsins for the Photocontrol of Calcium Signalling,” Nature Communications 13, no. 1 (2022): 7844.

[747] Q. Zhang, T. Li, M. Xu, B. Islam, and J. Wang, “Application of Optogenetics in Neurodegenerative Diseases,” Cellular and Molecular Neurobiology 44, no. 1 (2024): 57.

[748] D. Eldar, S. Albert, A. Tatyana, et al., “Optogenetic Approaches for Neural Tissue Regeneration: A Review of Basic Optogenetic Principles and Target Cells for Therapy,” Neural Regeneration Research 21, no. 2 (2026): 521–533.

[749] L. Madisen, T. Mao, H. Koch, et al., “A Toolbox of Cre-dependent Optogenetic Transgenic Mice for Light-induced Activation and Silencing,” Nature Neuroscience 15, no. 5 (2012): 793–802.

[750] D. A. Thompson, T. Tsaava, A. Rishi, et al., “Optogenetic Stimulation of the Brainstem Dorsal Motor Nucleus Ameliorates Acute Pancreatitis,” Frontiers in Immunology 14 (2023): 1166212.

[751] Y. Yun, X. Wang, J. Xu, et al., “Optogenetic Stimulation of Basal Forebrain Cholinergic Neurons Prevents Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice,” Behavioral and Brain Functions 19, no. 1 (2023): 11.

[752] A. M. Kressel, T. Tsaava, Y. A. Levine, et al., “Identification of a Brainstem Locus That Inhibits Tumor Necrosis Factor,” Proceedings of the National Academy of Sciences of of the United States of America 117, no. 47 (2020): 29803–29810.

[753] A. A. Rahman, R. Stavely, W. Pan, et al., “Optogenetic Activation of Cholinergic Enteric Neurons Reduces Inflammation in Experimental Colitis,” Cell Mol Gastroenterol Hepatol 17, no. 6 (2024): 907–921.

[754] K. J. Tracey, “Consolidating Roles of Neuro-immune Reflexes: Specificity of Afferent, central, and Efferent Signals in Homeostatic Immune Networks,” Genes & Development 38, no. 17–20 (2024): 805–807.

[755] A. Moreno, K. Endicott, M. Skancke, et al., “Sudden Heart Rate Reduction Upon Optogenetic Release of Acetylcholine from Cardiac Parasympathetic Neurons in Perfused Hearts,” Frontiers in Physiology 10 (2019): 16.

[756] C. McIntyre, X. F. Li, D. Ivanova, J. Wang, and K. T. O'Byrne, “Hypothalamic PVN CRH Neurons Signal through PVN GABA Neurons to Suppress GnRH Pulse Generator Frequency in Female Mice,” Endocrinology 164, no. 6 (2023): bqad075.

[757] S. Y. Xiong, H. Z. Wen, L. M. Dai, et al., “A Brain-tumor Neural Circuit Controls Breast Cancer Progression in Mice,” Journal of Clinical Investigation 133, no. 24 (2023): e167725.

[758] Y. Yang and Y. Tao, “Regenerating Locus Coeruleus-Norepinephrine (LC-NE) Function: A Novel Approach for Neurodegenerative Diseases,” Cell Proliferation 58, no. 6 (2025): e13807.

[759] F. S. Giorgi, F. Biagioni, A. Galgani, et al., “Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia,” International Journal of Molecular Sciences 21, no. 22 (2020): 8630.

[760] A. Torrillas-de la Cal, S. Torres-Sanchez, L. Bravo, et al., “Chemogenetic Activation of Locus Coeruleus Neurons Ameliorates the Severity of Multiple Sclerosis,” Journal of Neuroinflammation 20, no. 1 (2023): 198.

[761] M. H. Yi, Y. Liu, Y. U. Liu, et al., “Optogenetic Activation of Cortical Microglia Promotes Neuronal Activity and Pain Hypersensitivity,” Cell Reports 44, no. 5 (2025): 115717.

[762] A. K. Evans, H. H. Park, C. E. Woods, et al., “Impact of Noradrenergic Inhibition on Neuroinflammation and Pathophysiology in Mouse Models of Alzheimer's Disease,” Journal of Neuroinflammation 21, no. 1 (2024): 322.

[763] S. Tanaka, C. Abe, S. B. G. Abbott, et al., “Vagus Nerve Stimulation Activates Two Distinct Neuro-immune Circuits Converging in the Spleen to Protect Mice From Kidney Injury,” Proceedings of the National Academy of Sciences of of the United States of America 118, no. 12 (2021): e2021758118.

[764] Y. Kawana, J. Imai, Y. M. Morizawa, et al., “Optogenetic Stimulation of Vagal Nerves for Enhanced Glucose-stimulated Insulin Secretion and Beta Cell Proliferation,” Nature Biomedical Engineering 8, no. 7 (2024): 808–822.

[765] C. S. Mitchell, E. J. Campbell, S. D. Fisher, et al., “Optogenetic Recruitment of Hypothalamic Corticotrophin-releasing-hormone (CRH) Neurons Reduces Motivational Drive,” Translational Psychiatry 14, no. 1 (2024): 8.

[766] P. Tan, L. He, G. Han, and Y. Zhou, “Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity,” Trends in Biotechnology 35, no. 3 (2017): 215–226.

[767] Y. Ke, S. Liu, Y. Huang, T. H. Lan, and Y. Zhou, “Optogenetic Engineering for Precision Cancer Immunotherapy,” Trends in Pharmacological Sciences 46, no. 10 (2025): 1018–1037.

[768] K. Murray, K. M. Rude, J. Sladek, and C. Reardon, “Divergence of Neuro-immune Circuits Activated by Afferent and Efferent Vagal Nerve Stimulation in the Regulation of Inflammation,” The Journal of Physiology 599, no. 7 (2021): 2075–2084.

[769] V. A. Pavlov and K. J. Tracey, “Bioelectronic Medicine: Preclinical Insights and Clinical Advances,” Neuron 110, no. 21 (2022): 3627–3644.

[770] J. E. Park, Y. H. Leem, J. S. Park, et al., “Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an alpha7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models,” International Journal of Molecular Sciences 23, no. 8 (2022): 4420.

[771] R. J. De Marco, A. H. Groneberg, C. M. Yeh, L. A. Castillo Ramirez, and S. Ryu, “Optogenetic Elevation of Endogenous Glucocorticoid Level in Larval Zebrafish,” Frontiers in Neural Circuits 7 (2013): 82.

[772] C. Grimm, S. N. Duss, M. Privitera, et al., “Tonic and Burst-Like Locus Coeruleus Stimulation Distinctly Shift Network Activity Across the Cortical Hierarchy,” Nature Neuroscience 27, no. 11 (2024): 2167–2177.

[773] A. K. Brink, S. K. C. Lui, and L. H. Corbit, “Alpha-2 Agonism in the Locus Coeruleus Impairs Learning Driven by Negative Prediction Error,” Neuropsychopharmacology 50, no. 7 (2025): 1186–1193.

[774] Y. Yu, X. Wu, M. Wang, et al., “Optogenetic-controlled Immunotherapeutic Designer Cells for Post-surgical Cancer Immunotherapy,” Nature Communications 13, no. 1 (2022): 6357.

[775] Q. Lu, A. Wright, and Z. H. Pan, “AAV Dose-dependent Transduction Efficiency in Retinal Ganglion Cells and Functional Efficacy of Optogenetic Vision Restoration,” Gene Therapy 31, no. 11–12 (2024): 572–579.

[776] Y. Shen, R. E. Campbell, D. C. Cote, and M. E. Paquet, “Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans,” Frontiers in Neural Circuits 14 (2020): 41.

[777] Y. Lin, Y. Yao, W. Zhang, et al., “Applications of Upconversion Nanoparticles in Cellular Optogenetics,” Acta Biomaterialia 135 (2021): 1–12.

[778] A. M. Clark, A. Ingold, C. F. Reiche, et al., “An Optrode Array for Spatiotemporally-precise Large-scale Optogenetic Stimulation of Deep Cortical Layers in Non-human Primates,” Communications Biology 7, no. 1 (2024): 329.

[779] J. Cohen, A. Mathew, K. D. Dourvetakis, et al., “Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders,” Cells 13, no. 6 (2024): 511.

[780] A. Bar-Or, J. Nicholas, J. Feng, F. Sorrell, and M. Cascione, “Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management,” Neurology Neuroimmunology & Neuroinflammation 12, no. 4 (2025): e200427.

[781] M. Tolentino, F. Pace, D. C. Perantie, et al., “Cerebrospinal Fluid Biomarkers as Predictors of multiple sclerosis Severity,” Multiple Sclerosis and Related Disorders 94 (2025): 106268.

[782] L. Airas, E. Rissanen, and J. O. Rinne, “Imaging Neuroinflammation in Multiple Sclerosis Using TSPO-PET,” Clinical and Translational Imaging 3, no. 6 (2015): 461–473.

[783] L. Klotz, J. Smolders, J. Lehto, et al., “Broad Rim Lesions Are a New Pathological and Imaging Biomarker for Rapid Disease Progression in Multiple Sclerosis,” Nature Medicine 31, no. 6 (2025): 2016–2026.

[784] P. R. Warjukar, A. V. Mohabey, P. B. Jain, and G. R. Bandre, “Decoding the Correlation between Inflammatory Response Marker Interleukin-6 (IL-6) and C-reactive Protein (CRP) with Disease Activity in Rheumatoid Arthritis,” Cureus 16, no. 6 (2024): e62954.

[785] J. L. Bennett, S. J. Pittock, F. Paul, et al., “B Cell and Aquaporin-4 Antibody Relationships With neuromyelitis optica Spectrum Disorder Activity,” Annals of Clinical and Translational Neurology 11, no. 10 (2024): 2792–2798.

[786] V. Padureanu, D. Dop, R. Padureanu, et al., “Anti-NMDA Receptor Encephalitis: A Narrative Review,” Brain Sciences 15, no. 5 (2025): 518.

[787] C. Liu and E. S. Gershon, “Endophenotype 2.0: Updated Definitions and Criteria for Endophenotypes of Psychiatric Disorders, Incorporating New Technologies and Findings,” Translational Psychiatry 14, no. 1 (2024): 502.

[788] S. Poletti, M. G. Mazza, and F. Benedetti, “Inflammatory Mediators in Major Depression and Bipolar Disorder,” Translational Psychiatry 14, no. 1 (2024): 247.

[789] L. Orsolini, S. Pompili, S. Tempia Valenta, V. Salvi, and U. Volpe, “C-Reactive Protein as a Biomarker for Major Depressive Disorder?,” International Journal of Molecular Sciences 23, no. 3 (2022): 1616.

[790] A. Gasparini, C. Callegari, G. Lucca, et al., “Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: A Systematic Review and Meta-Analysis,” Psychopharmacology Bulletin 52 (2022): 1.

[791] Y. Kang, D. Shin, A. Kim, et al., “Resting-state Functional Connectivity Is Correlated With Peripheral Inflammatory Markers in Patients With Major Depressive Disorder and Healthy Controls,” Journal of Affective Disorders 370 (2025): 207–216.

[792] B. Guo, M. Zhang, W. Hao, et al., “Neuroinflammation Mechanisms of Neuromodulation Therapies for Anxiety and Depression,” Translational Psychiatry 13, no. 1 (2023): 5.

[793] F. Chauveau, A. Winkeler, S. Chalon, H. Boutin, and G. Becker, “PET Imaging of Neuroinflammation: Any Credible Alternatives to TSPO yet?,” Molecular Psychiatry 30, no. 1 (2025): 213–228.

[794] S. Salerno, M. Viviano, E. Baglini, et al., “TSPO Radioligands for Neuroinflammation: An Overview,” Molecules (Basel, Switzerland) 29, no. 17 (2024): 4212.

[795] F. Goffi, E. Maggioni, A. M. Bianchi, P. Brambilla, and G. Delvecchio, “Is Cardiac Autonomic Control Affected in Major Depressive Disorder? A Systematic Review of Heart Rate Variability Studies,” Translational Psychiatry 15, no. 1 (2025): 217.

[796] E. Kloter, K. Barrueto, S. D. Klein, F. Scholkmann, and U. Wolf, “Heart Rate Variability as a Prognostic Factor for Cancer Survival—A Systematic Review,” Frontiers in Physiology 9 (2018): 623.

[797] M. N. Jarczok, J. Koenig, and J. F. Thayer, “Lower Values of a Novel Index of Vagal-Neuroimmunomodulation Are Associated to Higher all-cause Mortality in Two Large General Population Samples With 18 Year Follow up,” Scientific Reports 11, no. 1 (2021): 2554.

[798] E. O. Sanya, M. Tutaj, C. M. Brown, et al., “Abnormal Heart Rate and Blood Pressure Responses to Baroreflex Stimulation in Multiple Sclerosis Patients,” Clinical Autonomic Research 15, no. 3 (2005): 213–218.

[799] Y. Nagai, C. I. Jones, and A. Sen, “Galvanic Skin Response (GSR)/Electrodermal/Skin Conductance Biofeedback on Epilepsy: A Systematic Review and Meta-Analysis,” Frontiers in Neurology 10 (2019): 377.

[800] M. E. Addorisio, G. H. Imperato, A. F. de Vos, et al., “Investigational Treatment of Rheumatoid Arthritis With a Vibrotactile Device Applied to the External Ear,” Bioelectronic Medicine 5 (2019): 4.

[801] S. Marsal, H. Corominas, J. J. de Agustin, et al., “Non-invasive Vagus Nerve Stimulation for Rheumatoid Arthritis: A Proof-of-concept Study,” The Lancet Rheumatology 3, no. 4 (2021): e262–e269.

[802] E. Goggins, S. Mitani, and S. Tanaka, “Clinical Perspectives on Vagus Nerve Stimulation: Present and Future,” Clinical Science (London, England: 1979) 136, no. 9 (2022): 695–709.

[803] H. Mado, A. Stasiniewicz, M. Adamczyk-Sowa, and P. Sowa, “Selected Interleukins Relevant to Multiple Sclerosis: New Directions, Potential Targets and Therapeutic Perspectives,” International Journal of Molecular Sciences 25, no. 20 (2024).

[804] V. Nociti and M. Romozzi, “The Role of BDNF in Multiple Sclerosis Neuroinflammation,” International Journal of Molecular Sciences 24, no. 9 (2023).

[805] B. McKee, S. Liu, P. X. Cai, et al., “Optogenetic Control of T Cells for Immunomodulation,” Essays in Biochemistry (2025).

[806] D. J. Jackson, M. E. Wechsler, G. Brusselle, and R. Buhl, “Targeting the IL-5 Pathway in Eosinophilic Asthma: A Comparison of Anti-IL-5 versus Anti-IL-5 Receptor Agents,” Allergy 79, no. 11 (2024): 2943–2952.

[807] W. Al Jumaili, D. Vora, C. Trivedi, and S. Jain, “Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials,” Primary Care Companion for CNS Disorders 25, no. 5 (2023).

[808] C. Barros, A. Barateiro, A. Neto, et al., “S100B inhibition Protects From Chronic Experimental Autoimmune Encephalomyelitis,” Brain Communications 4, no. 3 (2022): fcac076.

[809] D. Pukoli and L. Vecsei, “Kynurenines and Mitochondrial Disturbances in Multiple Sclerosis,” International Journal of Molecular Sciences 26, no. 11 (2025).

[810] M. Thomsen, C. Kersten, H. Sorbye, et al., “Interleukin-6 and C-reactive Protein as Prognostic Biomarkers in Metastatic Colorectal Cancer,” Oncotarget 7, no. 46 (2016): 75013–75022.

[811] W. Zhang, Y. Tan, Y. Li, and J. Liu, “Neutrophil to Lymphocyte Ratio as a Predictor for Immune-related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis,” Frontiers in Immunology 14 (2023): 1234142.

[812] H. Yang, L. Xia, J. Chen, et al., “Stress-glucocorticoid-TSC22D3 Axis Compromises Therapy-induced Antitumor Immunity,” Nature Medicine 25, no. 9 (2019): 1428–1441.

[813] Y. Gidron, M. De Couck, D. Schallier, et al., “The Relationship Between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers,” Journal of Immunology Research 2018 (2018): 4874193.

[814] S. Kurozumi, K. Kaira, H. Matsumoto, et al., “beta(2)-Adrenergic Receptor Expression Is Associated With Biomarkers of Tumor Immunity and Predicts Poor Prognosis in Estrogen Receptor-negative Breast Cancer,” Breast Cancer Research and Treatment 177, no. 3 (2019): 603–610.

[815] K. R. Keever, V. P. Yakubenko, and D. B. Hoover, “Neuro-immune Nexus in the Pathophysiology and Therapy of Inflammatory Disorders: Role of alpha7 Nicotinic Acetylcholine Receptors,” Pharmacological Research 191 (2023): 106758.

[816] X. Zhang, Q. Liu, Q. Liao, and Y. Zhao, “Potential Roles of Peripheral Dopamine in Tumor Immunity,” Journal of Cancer 8, no. 15 (2017): 2966–2973.

[817] O. Atar, R. Ram, I. Avivi, et al., “Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma,” Journal of Clinical Medicine 12, no. 3 (2023).

[818] H. Wang, R. Huo, K. He, et al., “Increased Nerve Density Adversely Affects Outcome in Colorectal Cancer and Denervation Suppresses Tumor Growth,” Journal of Translational Medicine 23, no. 1 (2025): 112.

[819] X. Li, X. Peng, S. Yang, et al., “Targeting Tumor Innervation: Premises, Promises, and Challenges,” Cell Death Discovery 8, no. 1 (2022): 131.

[820] S. Huang, J. Zhu, L. Yu, Y. Huang, and Y. Hu, “Cancer-nervous System Crosstalk: From Biological Mechanism to Therapeutic Opportunities,” Molecular Cancer 24, no. 1 (2025): 133.

[821] M. P. Kilgard, J. D. Epperson, E. A. Adehunoluwa, et al., “Closed-loop Vagus Nerve Stimulation Aids Recovery From Spinal Cord Injury,” Nature 643, no. 8073 (2025): 1030–1036.

[822] K. Murray, M. Cremin, E. Tay, et al., “Inhibition of Acute Lung Inflammation by a Neuro-immune Circuit Induced by Vagal Nerve Stimulation,” Science Advances 11, no. 23 (2025): eadw7080.

[823] K. Y. Fjaestad, A. M. A. Romer, V. Goitea, et al., “Blockade of Beta-adrenergic Receptors Reduces Cancer Growth and Enhances the Response to Anti-CTLA4 Therapy by Modulating the Tumor Microenvironment,” Oncogene 41, no. 9 (2022): 1364–1375.

[824] J. G. Skeate, D. M. Da Silva, E. Chavez-Juan, et al., “Nano-Pulse Stimulation Induces Immunogenic Cell Death in human Papillomavirus-transformed Tumors and Initiates an Adaptive Immune Response,” PLoS ONE 13, no. 1 (2018): e0191311.

[825] B. M. Arciga, D. M. Walters, E. T. Kimchi, et al., “Pulsed Electric Field Ablation as a Candidate to Enhance the Anti-tumor Immune Response to Immune Checkpoint Inhibitors,” Cancer Letters 609 (2025): 217361.

[826] B. Markelc, T. Jesenko, and S. Kranjc Brezar, “Non-clinical Evaluation of pmIL12 Gene Therapy for Approval of the Phase I Clinical Study,” Scientific Reports 14, no. 1 (2024): 22288.

[827] B. Lisec, B. Markelc, K. Ursic Valentinuzzi, G. Sersa, and M. Cemazar, “The Effectiveness of Calcium Electroporation Combined With Gene Electrotransfer of a Plasmid Encoding IL-12 Is Tumor Type-dependent,” Frontiers in Immunology 14 (2023): 1189960.

[828] L. C. Booth, S. T. Yao, A. Korsak, et al., “Selective Optogenetic Stimulation of Efferent Fibers in the Vagus Nerve of a Large Mammal,” Brain Stimulation 14, no. 1 (2021): 88–96.

[829] I. T. Mughrabi, J. Hickman, N. Jayaprakash, et al., “Development and Characterization of a Chronic Implant Mouse Model for Vagus Nerve Stimulation,” Elife 10 (2021): e61270.

[830] G. S. Hong, A. Zillekens, B. Schneiker, et al., “Non-invasive Transcutaneous Auricular Vagus Nerve Stimulation Prevents Postoperative Ileus and Endotoxemia in Mice,” Neurogastroenterology and Motility 31, no. 3 (2019): e13501.

[831] A. D. Hughes, D. T. Teachey, and C. Diorio, “Riding the Storm: Managing Cytokine-related Toxicities in CAR-T Cell Therapy,” Seminars in Immunopathology 46, no. 3–4 (2024): 5.

[832] C. Aranow, Y. Atish-Fregoso, M. Lesser, et al., “Transcutaneous Auricular Vagus Nerve Stimulation Reduces Pain and Fatigue in Patients With Systemic Lupus Erythematosus: A Randomised, Double-blind, Sham-controlled Pilot Trial,” Annals of the Rheumatic Diseases 80, no. 2 (2021): 203–208.

[833] I. Lerman, Y. Bu, R. Singh, et al., “Next Generation Bioelectronic Medicine: Making the Case for Non-invasive Closed-loop Autonomic Neuromodulation,” Bioelectronic Medicine 11, no. 1 (2025): 1.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.